medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Title:

A systematic review and meta-analysis comparing the diagnostic accuracy tests of COVID-19

Juan Jeferson Vilca-Alosilla[1,2,†], Mayron Antonio Candia-Puma[1,2,†], Katiusca Coronel-Monje[1,2], Luis Daniel Goyzueta-Mamani[1,3], Alexsandro Sobreira Galdino[4], Ricardo Andrez Machado-de-Ávila[5], Rodolfo Cordeiro Giunchetti[6,7], Eduardo Antonio Ferraz Coelho[8,9], Miguel Angel Chávez-Fumagalli[1, *]

[1]Computational Biology and Chemistry Research Group, Vicerrectorado de Investigación, Universidad Católica de Santa María, Arequipa 04000, Peru.
[2]Facultad de Ciencias Farmacéuticas, Bioquímicas y Biotecnológicas, Universidad Católica de Santa María, Arequipa 04000, Peru.
[3]Sustainable Innovative Biomaterials Department, Le Qara Research Center, Arequipa 04000, Peru.
[4]Laboratório de Biotecnologia de Microrganismos, Universidade Federal São João Del-Rei, Divinópolis 35501-296, MG, Brazil.
[5]Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, Criciúma 88806-000, SC, Brazil
[6]Laboratório de Biologia das Interações Celulares, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
[7]Instituto Nacional de Ciência e Tecnologia em Doenças Tropicais, INCT-DT, Salvador 40015-970, BA, Brazil.
[8]Programa de Pós-Graduação em Ciências da Saúde: Infectologia e Medicina Tropical, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
[9]Departamento de Patologia Clínica, COLTEC, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.

[†]These authors contributed equally to this work.

[*] Correspondence E-mail: mchavezf@ucsm.edu.pe

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract

In this work, we report a systematic review and meta-analysis that seeks to analyze the accuracy of diagnostic tests for coronavirus disease 2019 (COVID-19). The objective of this article is to detail the scientific findings based on diagnostic tests of the last years when the pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred. Searches for published studies were carried out in the PubMed database between the years 2020 and 2021 for the diagnosis of COVID-19. Ninety-nine scientific articles that met the criteria were examined and accepted in the meta-analysis, and the diagnostic accuracy was evaluated through specificity and sensitivity. Molecular tests [Reverse transcription polymerase chain reaction (RT-PCR), reverse transcription loop-mediated isothermal amplification (RT-LAMP), and clustered regularly interspaced short palindromic repeats (CRISPR)] showed better performance in terms of sensitivity and specificity when compared to serological tests [Enzyme-linked immunosorbent assay (ELISA), chemiluminescence immunoassay (CLIA), lateral flow immunoassay (LFIA), chemiluminescent microparticle immunoassays (CMIA), and Fluorescence immunoassay (FIA)], which showed higher specificity, mainly for the detection of IgG antibodies; however, they showed sensitivity <90%. In addition, the antiviral neutralization bioassay (ANB) diagnostic test demonstrated high potential for the diagnosis of COVID-19, since it obtained the highest area under the curve restricted to the false-positive rates (AUC_{FPR}) of 0.984. It is settled that the different diagnostic tests have been efficiently adapted for the detection of SARS-CoV-2; however, their performance still needs to be optimized to control future outbreaks of COVID-19, which will also serve to help the control of future infectious agents.

Keywords: SARS-CoV-2; Diagnostic Tests; Meta-analysis; Systematic Review; Sensitivity; Specificity.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported at the end of 2019 in Wuhan, Hubei province, China [1]. On 11 March 2020, the World Health Organization (WHO) declared COVID-19 a pandemic, due to the high levels of spread worldwide [2]. The virus is transmitted by direct contact with an infected person, by the expulsion of droplets and small particles when breathing, speaking, or coughing, or by drops of saliva with the virus being deposited on surfaces and/or objects, which are transmitted through touch [3,4]. According to the WHO, by September 2022, around 600 million confirmed cases of COVID-19 have been reported worldwide, including more than 6 million deaths [5]. Likewise, the transmission of the virus by asymptomatic people is a major concern for community spread [6], where a study indicates that 35.1% of patients with COVID-19 did not present symptoms [7]; in this context, so an early diagnosis of infection would allow the rapid spread of the virus to be controlled [8]. It was estimated that a single symptomatic COVID-19 infection would have an average direct medical cost during infection condition of US$3 045, which would increase to $14 366 per hospitalization [9], making COVID-19 one of the greatest and most significant global health crises crisis in human history.

The pathogenicity of SARS-CoV-2 is fundamentally related to the interaction of the virus S protein and host membrane receptor angiotensin-converting enzyme 2 (ACE2) [10]. COVID-19 affects not only the respiratory system but also other organs, such as the liver and kidneys [11]. Generally, the clinical manifestations of COVID-19 are diverse, while the most prevalent symptoms are fever, cough, dyspnea, malaise, fatigue, neurological symptoms, dermatological manifestations, anorexia, myalgia, sneezing, sore throat, rhinitis, goosebumps, headache, chest pain, and diarrhea [12,13]. The symptoms that SARS-CoV-2 induces in several patients are mild, but may also be related to an accelerated onset of generalized infection in the lungs that is complicated by acute respiratory distress syndrome (ARDS) [14,15], due to an unregulated inflammatory/immune system and cytokine storm [16]. In addition, a series of possible late complications due to COVID-19 infection has been pointed out, including venous thromboembolism, arterial thrombosis, pulmonary fibrosis, cardiac thrombosis and inflammation, cerebrovascular accident, mental fog, dermatological complications, and overall mood dysfunctions [17].

Control strategies against the spread of COVID-19 in many countries initially focused on complete or partial lockdowns. Still, these measures were not as effective due to the rapid increase in the number of hospitalized infected people [16]. Several vaccines have been licensed to reduce the incidence of hospitalization and death; despite this vaccination coverage remains insufficient [18,19], and many of them may not be effective against new virus variants [20]. Symptomatic treatment instead of curative treatment has been the fundamental tool for the treatment of critically ill patients through ventilatory support in the intensive care unit [21]. Other potential therapeutic strategies include antiviral, antibiotic, and immunomodulatory therapies [22]. For this reason, diagnostic tools continue to play a crucial role in the battle against COVID-19, allowing rapid implementation of control measures to suppress SARS-CoV-2 transmission through case identification, contact tracing, and isolation of positive cases [23,24].

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

At the beginning of the COVID-19 pandemic, no efficient diagnostic test was available for patients who became severely ill, and the diagnosis was based mainly on the patient's clinical manifestations and exposure history. With the SARS-CoV-2 genome sequenced, WHO produced the protocol for the molecular diagnosis of COVID-19 based on real-time RT-PCR, allowing the development of commercial diagnostic kits [25]. Real-time RT-PCR is the current reference laboratory test, considered the "*gold standard*" for its high sensitivity and specificity [26]. However, despite the high diagnostic accuracy, the high cost, the need for ribonucleic acid (RNA) extraction, the availability of specialized raw materials, and the relatively long execution time, makes it is difficult to be applied on a large scale [27,28]. On the other side, serological tests are reliable, simple, and inexpensive techniques that allow direct and indirect detection of infections; however, they detect the presence of antibodies as a marker of past infection [29]. Serologic assays such as Enzyme-Linked Immunosorbent Assay (ELISA), Chemiluminescent Immunoassay (CLIA), and Lateral Flow Immunochromatographic Assay (LFIA) are used as diagnostic tools, often for the detection of IgA, IgG, and IgM antibodies from the patient's serum or plasma, which are directed against the spike (S) and the nucleocapsid (N) proteins of SARS-CoV-2 [30]. The timing of immunoglobulin production (from 4 days after the onset of symptoms to 10-14 days) limits its applicability in acute phase diagnosis, however, by detecting IgM and IgA that is rapidly formed in response to infection, may represent a tool that can help diagnose COVID-19, as well as significantly increase diagnostic sensitivity by combining serological tests with molecular tests [31,32]. COVID-19 antigen tests allow the diagnosis of active infection by detecting the proteins of the SARS-CoV-2 virus in different types of samples. They are available as single-use, lateral flow, rapid antigen detection diagnostic tests, which can be read visually or processed and read with a small handheld device. Both can be performed outside a laboratory and provide results in 15 to 20 minutes. These tests can be produced faster and applied on a larger scale. While these tests can be very specific, they are generally not as sensitive as molecular tests [33–35].

The present study aims to systematically review and summarize the available literature on the diagnostic accuracy of COVID-19 diagnostic tests. In this sense, a systematic review of the literature was carried out and the results were analyzed through a meta-analysis based on the techniques developed and used for the diagnosis of COVID-19. The diagnostic techniques analyzed were reverse transcription–polymerase chain reaction (RT-PCR), reverse transcriptase loop-mediated isothermal amplification (RT-LAMP), clustered regularly interspaced short palindromic repeats (CRISPR), microarrays (MA), next-generation sequencing (NGS), enzyme-linked immunosorbent assay (ELISA), antiviral neutralization bioassay (ANB), biosensors (BS), chemiluminescence immunoassay (CLIA), lateral flow immunoassay (LFIA), chemiluminescent microparticle immunoassay (CMIA), electrochemiluminescence immunoassay (ECLIA) and fluorescence immunoassay (FIA). Therefore, we hope that the data generated will help identify the most effective diagnostic techniques against new pathogens such as SARS-CoV-2 and its variants.

Methods

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Search strategy

This systematic review was based on the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) technique [36], and this systematic review protocol has been registered on INPLASY (https://inplasy.com/inplasy-2022-9-0132), while the registration number is INPLASY202290132. The search was carried out and conducted until 10 June 2022 in the PubMed database (https://pubmed.ncbi.nlm.nih.gov/). PubMed is one of the most widely used search engines for biomedical literature, developed and supported by the US NLM/National Center for Biotechnology Information (NCBI) [37]. The search for the terms associated in the literature with the diagnosis of COVID-19 was carried out using the MeSH term "COVID-19", the results were shown in a co-occurrence network map of MeSH terms in the VOSviewer software (version 1.6.18) [38]. The clusters in the network map were analyzed to choose relevant terms associated with COVID-19 diagnostic techniques. Additionally, a second search was developed with each MeSH term obtained in the cluster analysis, relating the MeSH term "sensitivity and specificity", which are normally typically considered a parameter for the evaluation of the diagnostic accuracy of a test [39], and the MeSH term "COVID -19".

Search strategy, eligibility criteria, and data extraction

The studies included in the meta-analysis were chosen in three stages. In the first stage duplicate articles, articles in languages other than English, reviews, and meta-analyses were excluded. In the second stage of the screening stage, the titles and abstracts of the articles found through the search strategy were analyzed. Finally, in the eligibility stage, the complete studies with high relevance were obtained, and they were isolated from the articles with a title or abstract that did not provide sufficient data to be considered within the meta-analysis. The information extracted from each selected study included the diagnostic technique, the number, type, and clinical characteristics of the patients with COVID-19, and healthy controls. All studies evaluating diagnostic accuracy using sensitivity and specificity parameters have been included. Likewise, the data related to the geographical distribution, the number of studies related by country, and the frequency of the diagnostic techniques used were extracted. Studies lack data of Studies with unclear or lacking data regarding the sensitivity and specificity of COVID-19 diagnostic tests were excluded from further analysis.

Statistical analysis

Results were entered into Microsoft Excel (version 10.0, Microsoft Corporation, Redmond, WA, USA) spreadsheets and analyzed in the R programming environment (version 4.2.1) using the package *"mada"* (version 0.5.11) https://cran.r-project.org/web/packages/mada/index.html; which employs a hierarchical model that accounts for within and between-study (heterogeneity) and the correlation between sensitivity and specificity [40]. Initially, the number of true negatives (TP), false negatives (FN), true positives (TP), and false positives (FP) were analyzed separately for each diagnostic technique; while the evaluation of sensitivity (Se) and specificity (Sp) made it possible to determine the diagnostic performance. Additionally, the positive likelihood ratio (LR+) expresses the ratio between the probability of expecting a positive test in a patient and the probability of expecting a positive test in a patient without the disease [41];

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

the negative likelihood ratio (LR−), which expresses the probability that a patient will test negative among people with the disease and the probability that a patient will test negative among people without disease; and the diagnostic likelihood ratio (DOR), which is the odds ratio of the positivity of a diagnostic test result in the diseased population relative to the non-diseased population [42]; and the 95% confidence interval (CI) were determined. Summary receiver operating characteristic (sROC) curves were fitted, according to the parameters of the *"Reitsma"* model of the *"mada"* package, and were used to compare the diagnostic accuracy of COVID-19 diagnostic techniques [43]. The confidence level for all calculations was set to 95%, using a continuity correction of 0.5 if pertinent.

Results

Data sources and study selection

In this study, a systematic review followed by meta-analysis was performed to measure the accuracy of diagnostic tests for COVID-19. A flowchart of the study strategy was prepared and presented (Figure 1). To this end, a search was accomplished in the PubMed database with the MeSH terms "COVID-19", and a co-occurrence network map of MeSH terms was developed; Through the search, 981 scientific articles were obtained between the years 2020 and 2021. The minimum number of occurrences of keywords was set at a value of five, and a network map with 2.518 keywords was generated (Figure 2A). The formation of five main clusters was found in the analysis of the network map, in the cluster related to diagnostic techniques (purple color) terms such as *"Reverse Transcription–Polymerase Chain Reaction", "Reverse Transcriptase Loop-Mediated Isothermal Amplification", "Clustered Regularly Interspaced Short Palindromic Repeats", "Microarrays", "Next-Generation Sequencing", "Enzyme-Linked Immunosorbent Assay", "Antiviral Neutralization Bioassay", "Biosensor"* and *"Immunoassay".* In addition, terms such as *"COVID-19", "SARS-COV-2", "adult", China", "disease outbreaks middle-aged",* and *"female"* were common denominators (Figure 2A).

A second search was performed in the PubMed database with the terms found in the first analysis. The new terms were associated with the terms "*COVID-19*" and "*Sensitivity and Specificity*"; generating the new search strings: (Covid 19[MeSH Terms]) AND (sensitivity and specificity[MeSH Terms]) AND (RT-PCR[MeSH Terms]) for RT-PCR; (Covid 19[MeSH Terms]) AND (sensitivity and specificity[MeSH Terms]) AND (RT-LAMP assay[MeSH Terms]) for RT-LAMP; (Covid 19[MeSH Terms]) AND (sensitivity and specificity[MeSH Terms]) AND (CRISPR[MeSH Terms]) for CRISPR; (Covid 19[MeSH Terms]) AND (sensitivity and specificity[MeSH Terms]) AND (Microarray Analysis[MeSH Terms]) for MA; (Covid 19[MeSH Terms]) AND (sensitivity and specificity[MeSH Terms]) AND (Next generation sequencing[MeSH Terms]) for NGS; (Covid 19[MeSH Terms]) AND (sensitivity and specificity[MeSH Terms]) AND (ELISA[MeSH Terms]) for ELISA; (Covid 19[MeSH Terms]) AND (sensitivity and specificity[MeSH Terms]) AND (Neutralization Tests[MeSH Terms]) for ANB; (Covid 19[MeSH Terms]) AND (sensitivity and specificity[MeSH Terms]) AND (Biosensing Technique[MeSH Terms]) for BS; and (Covid 19[MeSH Terms]) AND (sensitivity and specificity[MeSH Terms]) AND (Immunoassay[MeSH Terms]) for immunoassays.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

The number of studies chosen for RT-PCR, RT-LAMP, CRISPR, MA, NGS, ELISA, ANB, BS, and immunoassays were: 303, 3, 14, 3, 16, 145, 35, 95, and 367, respectively (Figure 2B). The three-step eligibility criterion allowed 303, 369, and 215 articles to be excluded, from the criteria for identification, screening, and eligibility, respectively. Therefore, 99 articles were selected for meta-analysis (Figure 3). It is observed that in most studies, the diagnostic techniques used were immunoassays (CLIA, LFIA, CMIA, ECLIA, and FIA) (Figure 3A). Additionally, China, the United States of America, and India are the countries that have carried out a higher number of studies related to diagnostic tests for COVID-19 (Figures 3B and 3C).

Meta-analysis of the diagnostic techniques for COVID-19

Reverse transcription–polymerase chain reaction

Fifteen studies based on the RT-PCR technique were selected [44–58], in which a total of 6,902 subjects were studied. Sensitivity ranged from 36.8% to 99.2%, with a median of 94.5%, 95%CI (85.1, 98.0), while the test for equality of sensitivities presented a χ^2 = 577.02, df = 38, p-value = $2e^{-16}$. Specificity ranged from 79.3 to 99.8%, with a median of 98.4%, 95%CI (86.7, 99.8); the test for equality of specificities showed χ^2 = 142.18, df = 38, p-value = $5.96e^{-14}$. A negative correlation between sensitivities and false positive rates is shown r = –0.188, 95%CI (–0.476, 0.135). Additionally, results regarding LR+ {median 45.00, 95%CI (4.06, 563.27)}, LR− {median 0.06, 95%CI (0.02, 0.18)} and DOR {median 609.00, 95%CI (54.53, 8485.95)}. The analyzed diagnostic performance is summarized in Figure 4 and Supplementary Figure 1.

Reverse transcriptase loop-mediated isothermal amplification

Seven studies were selected using the RT-LAMP technique [59–65]. A total of 1,806 subjects were studied. Sensitivity ranged from 74.7 to 98.8%, with a median of 91.9%, 95%CI (80.0, 97.0); while the test for equality of sensitivities showed: χ^2 = 30.09, df =7, p-value = $9.12e^{-05}$. Specificity ranged from 88.1 to 99.6%, with a median of 98.8%, 95%CI (90.0, 100.0); while the test for equality of specificities presented χ^2 = 34.71, df = 7, p-value = $1.27e^{-05}$. The correlation between sensitivities and false positive rates was analyzed a negative result is shown r = 0.313, 95%CI (-0.502, 0.834). In addition, results regarding LR+ {median 69.51, 95%CI (4.88, 755.24)}, LR− {median 0.09, 95%CI (0.03, 0.23)} and DOR {median 801.74, 95%CI (48.36, 10044.33)} are displayed. The analyzed diagnostic performance is summarized in Figure 5 and Supplementary Figure 2.

Clustered regularly interspaced short palindromic repeats

The analysis identified 14 published studies that used CRISPR as a diagnostic tool. After analysis, only 7 seven studies [66–72] were selected. A total of 1,201 subjects were studied. Sensitivity ranged from 67.0 to 99.5%, with a median of 94.4%, and 95%CI (84.0, 99.0). Test for equality of sensitivities analysis showed: χ^2 = 80.26, df = 10, p-value = $4.47e^{-13}$. Specificity ranged from 83.6 to 99.6%, with a median of 98.6%, 95%CI (93.0, 100.0); while the test for equality of specificities: χ^2 = 55.37, df = 10, p-value = $2.69e^{-08}$. Also, a negative correlation between sensitivities and false positive rates is shown r = 0.328, 95%CI (–0.339, 0.775). In addition, results regarding LR+ {median 70.33, 95%CI (6.80, 898.96)}, LR− {median 0.06, 95%CI (0.01, 0.20)} and DOR {median 1357, 95%CI

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

(37.27, 29912.15)} are displayed. The diagnostic performance of the selected studies is summarized in Figure 6 and Supplementary Figure 3.

Enzyme-linked immunosorbent assay for IgG

Sixteen studies were selected using IgG-detecting ELISA as a diagnostic technique [73–88]. A total of 9,221 subjects were studied. Sensitivity ranged from 61.6 to 99.0%, with a median of 88.3%, 95%CI (80.3, 93.5), while the test for equality of sensitivities presented a χ^2 = 151.80, df = 22, p-value = $2e^{-16}$. Specificity ranged from 81.3 to 99.7%, with a median of 97.4%, 95%CI (89.6, 98.9); the test for equality of specificities showed χ^2 = 135.69, df = 22, p-value = $2e^{-16}$. A negative correlation between sensitivities and false positive rates is shown r = 0.166, 95%CI (–0.264, 0.541). In addition, the results regarding LR+ {median 29.99, 95%CI (5.78, 80.78)}, LR− {median 0.12, 95%CI (0.06, 0.23)} and DOR {median 333.00, 95%CI (37.03, 1288.51)}. The analyzed diagnostic performance is summarized in Figure 7 and Supplementary Figure 4.

Enzyme-linked immunosorbent assay for IgM

Five studies were selected using IgM-detecting ELISA as a diagnostic tool [74,84,87,89,90], in which a total of 1,585 subjects were studied. Sensitivity ranged from 46.9% to 99.7%, with a median of 73.1%, 95%CI (57.3, 78.8), while the test for equality of sensitivities presented a χ^2 = 150.59, df = 4, p-value = $2e^{-16}$. Specificity ranged from 89.3 to 99.8%, with a median of 98.1%, 95%CI (92.3, 99.6); the test for equality of specificities showed χ^2 = 28,12, df = 4, p-value = $1.18e^{-05}$. A negative correlation between sensitivities and false positive rates is shown r = 0.446, 95%CI (–0.719, 0.953). Additionally, results regarding LR+ {median 25.90, 95%CI (9.29, 127.19)}, LR− {median 0.27, 95%CI (0.21, 0.53)} and DOR {median 546.65, 95%CI (33.36, 8956.27)}. The analyzed diagnostic performance is summarized in Figure 8 and Supplementary Figure 5.

Enzyme-linked immunosorbent assay for IgA

Five studies were selected using IgA-detecting ELISA as a diagnostic technique [74,75,77,89,90]. A total of 1,632 subjects were studied. Sensitivity ranged from 79.8 to 92.4%, with a median of 83.7%, 95%CI (77.9, 88.8);), while the test for equality of sensitivities showed: χ^2 = 13.71, df =4, p-value = $8.25e^{-03}$. Specificity ranged from 85.6 to 99.6%, with a median of 98.0%, 95%CI (92.3, 99.1); while the test for equality of specificities presented χ^2 = 34.46, df = 4, p-value = $6.00e^{-07}$. The correlation between sensitivities and false positive rates was analyzed a negative result is shown r = -0.448, 95%CI (-0.953, 0.718). In addition, the results regarding LR+ {median 39.92, 95%CI (9.80, 85.62)}, LR− {median 0.18, 95%CI (0.13, 0.24)} and DOR {median 194.04, 95%CI (85.07, 442.62)} are displayed. The analyzed diagnostic performances are summarized in Figure 9 and Supplementary Figure 6.

Antiviral neutralization bioassay

The analysis identified 40 studies that used ANB as a diagnostic technique for COVID-19. After analysis, only 5 five studies [91–95] were selected. A total of 1,567 subjects were studied. Sensitivity ranged from 90.2 to 98.8%, with a median of 95.6%, and 95%CI (90.0, 98.0). Test for equality of sensitivities analysis showed: χ^2 = 19.18, df = 4, p-value

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

= 7.23e^{-04}. The specificity of the studies ranged from 98.7 to 99.8%, with a median of 99.5%, 95%CI (96.0, 100.0); while the test for equality of specificities: χ^2 = 3.21, df = 4, p-value = 0.52. Also, a negative correlation between sensitivities and false positive rates is shown r = -0.055, 95%CI (–0.894, 0.869). In addition, results regarding LR+ {median 185.17, 95%CI (22.71, 2950.41)}, LR− {median 0.04, 95%CI (0.02, 0.10)} and DOR {median 6332.92, 95%CI (458.41, 56606.18)} are displayed. The diagnostic performance of the selected studies is summarized in Figure 10 and Supplementary Figure 7.

Biosensors

Seven studies were selected using BS as a diagnostic technique [96–102]. A total of 814 subjects were studied. Sensitivity ranged from 90.0 to 98.8%, with a median of 96.4%, and CI of 95% (85.9, 99.2), while the test for equality of sensitivities presented a χ^2 = 6.63, df = 6, p-value = 0.35. Specificity ranged from 89.3 to 99.5%, with a median of 97.4%, 95%CI (93.1, 99.5); the test for equality of specificities showed χ^2 = 17.31, df = 6, p-value = 0.01. A negative correlation between sensitivities and false positive rates is shown r = 0.385, 95%CI (–0.882, 0.518). In addition, results regarding LR+ {median 36.15, 95%CI (8.24, 297.95)}, LR− {median 0.04, 95%CI (0.01, 0.19)} and DOR {median 459.96, 95%CI (129.02, 4295.06)}. The analyzed diagnostic performance is summarized in Figure 11 and Supplementary Figure 8.

Chemiluminescence immunoassay for IgG

Eight studies were selected using CLIA as an IgG detection technique [76,77,79,88,103–107], in which a total of 2,859 subjects were studied. Sensitivity ranged from 53.1% to 96.5%, with a median of 79.8%, 95%CI (65.3, 89.7), while the test for equality of sensitivities presented a χ^2 = 111.96, df = 11, p-value = 2e^{-16}. Specificity ranged from 89.8 to 99.9%, with a median of 98.7%, 95%CI (93.5, 99.6); the test for equality of specificities showed χ^2 = 47.84, df = 11, p-value = 1.53e^{-06}. A negative correlation between sensitivities and false positive rates is shown r = 0.319, 95%CI (–0.312, 0.755). Additionally, results regarding LR+ {median 62.27, 95%CI (7.99, 248.31)}, LR− {median 0.21, 95%CI (0.11, 0.38)} and DOR {median 286.73, 95%CI (46.74, 2894.79)}. The analyzed diagnostic performance is summarized in Figure 12 and Supplementary Figure 9.

Chemiluminescence immunoassay for IgM

Five studies were selected using CLIA as an IgM detection technique [77,79,103,104,106]. A total of 1,240 subjects were studied. Sensitivity ranged from 58.7 to 89.5%, with a median of 61.7%, 95%CI (53.0, 77.0);), while the test for equality of sensitivities showed: χ^2 = 18.52, df =4, p-value = 9.76e^{-04}. Specificity ranged from 91.3 to 99.5%, with a median of 99.2%, 95%CI (94.0, 100.0); while the test for equality of specificities presented χ^2 = 13.50, df = 4, p-value = 9.06e^{-03}. The correlation between sensitivities and false positive rates was analyzed a negative result is shown r = -0.252, 95%CI (-0.928, 0.810). In addition, results regarding LR+ {median 85.65, 95%CI (7.46, 1361.54)}, LR− {median 0.40, 95%CI (0.27, 0.48)} and DOR {median 250.76, 95%CI (18.56, 3396.17)} are displayed. The analyzed diagnostic performances are summarized in Figure 13 and Supplementary Figure 10.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Chemiluminescence immunoassay for IgM-IgG

The analysis identified 28 published studies that used CLIA to detect IgM-IgG antibodies for COVID-19. After analysis, only five studies [77,85,103,106,108] were selected. A total of 1,008 subjects were studied. Sensitivity ranged from 64.2 to 98.8%, with a median of 90.1%, and 95%CI (80.0, 95.0). Test for equality of sensitivities analysis showed: χ^2 = 51.25, df = 6, p-value = $2.64e^{-09}$. The specificity of the studies ranged from 97.7 to 99.5%, with a median of 99.2%, 95%CI (93.0, 100.0);), while the test for equality of specificities: χ^2 = 1.73, df = 6, p-value = 0.94. Also, a negative correlation between sensitivities and false positive rates is shown r = 0.635, 95%CI (–0.226, 0.939). In addition, results regarding LR+ {median 106.45, 95%CI (7.03, 1685.99)}, LR− {median 0.10, 95%CI (0.05, 0.22)} and DOR {median 828.39, 95%CI (45.47, 15090.85)} are displayed. The diagnostic performance of the selected studies is summarized in Figure 14 and Supplementary Figure 11.

Lateral flow immunoassay for IgG

Eleven studies were selected using LFIA as an IgG detection technique [75,77,79,109–116]. A total of 15,935 subjects were studied. Sensitivity ranged from 35.9 to 97.4%, with a median of 87.3%, 95%CI (76.5, 91.9), while the test for equality of sensitivities presented a χ^2 = 666.12, df = 21, p-value = $2e^{-16}$. Specificity ranged from 88.5 to 99.6%, with a median of 97.9%, 95%CI (95.5, 99.3); the test for equality of specificities showed χ^2 = 48.01, df = 21, p-value = $6.85e^{-04}$. A negative correlation between sensitivities and false positive rates is shown r = 0.175, 95%CI (–0.267, 0.555). In addition, results regarding LR+ {median 40.07, 95%CI (11.54, 131.19)}, LR− {median 0.13, 95%CI (0.08, 0.25)} and DOR {median 502.97, 95%CI (56.53, 1796.41)}. The analyzed diagnostic performance is summarized in Figure 15 and Supplementary Figure 12.

Lateral flow immunoassay for IgM

Six studies were selected using LFIA as an IgM detection technique [75,77,79,111,112,115], in which a total of 2,704 subjects were studied. Sensitivity ranged from 23.3% to 87.2%, with a median of 62.4%, 95%CI (51.1, 72.5), while the test for equality of sensitivities presented a χ^2 = 208.82, df = 11, p-value = $2e^{-16}$. Specificity ranged from 89.7 to 99.7%, with a median of 98.0%, 95%CI (93.7, 99.7); the test for equality of specificities showed χ^2 = 40.45, df = 11, p-value = $3.00e^{-05}$. A negative correlation between sensitivities and false positive rates is shown r = 0.153, 95%CI (–0.461, 0.669). Additionally, results regarding LR+ {median 33.70, 95%CI (5.07, 263.29)}, LR− {median 0.38, 95%CI (0.29, 0.51)} and DOR {median 96.36, 95%CI (13.50, 651.54)}. The analyzed diagnostic performance is summarized in Fig. 16 and Supplementary Figure 13.

Lateral flow immunoassay for IgM-IgG

Nine studies were selected using LFIA as an IgM-IgG detection technique [75,77,85,90,108,109,115,117,118]. A total of 9,629 subjects were studied. Sensitivity ranged from 44.1 to 97.0%, with a median of 83.7%, 95%CI (63.4, 88.2);), while the test for equality of sensitivities showed: χ^2 = 339.59, df =20, p-value = $2e^{-16}$. Specificity of the studies ranged from 87.4 to 99.5%, with a median of 97.1%, 95%CI (92.4, 99.7); while the test for equality of specificities presented χ^2 = 107.85, df = 20, p-value = $4.83e^{-14}$. The correlation between sensitivities and false positive rates was analyzed a negative result

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

is shown r = 0.279, 95%CI (-0.173, 0.635). In addition, results regarding LR+ {median 30.97, 95%CI (6.32, 445.62)}, LR− {median 0.18, 95%CI (0.13, 0.39)} and DOR {median 334.86, 95%CI (22.18, 2704.72)} are displayed. The analyzed diagnostic performances are summarized in Figure 17 and Supplementary Figure 14.

Lateral flow immunoassay for N protein

Fourteen studies were selected using LFIA as an N protein detection technique [119–132]. A total of 11,750 subjects were studied. Sensitivity ranged from 18.3 to 96.9%, with a median of 74.7%, 95%CI (50.7, 88.3), while the test for equality of sensitivities presented a χ^2 = 145.62, df = 21, p-value = $2e^{-16}$. Specificity ranged from 93.8 to 99.9%, with a median of 99.4%, 95%CI (95.9, 99.8); the test for equality of specificities showed χ^2 = 56.33, df = 21, p-value = $4.51e^{-05}$. A negative correlation between sensitivities and false positive rates is shown r = 0.193, 95%CI (–0.249, 0.568). In addition, results regarding LR+ {median 85.90, 95%CI (12.25, 482.92)}, LR− {median 0.26, 95%CI (0.12, 0.54)} and DOR {median 501.51, 95%CI (46.03, 2611.02)}. The analyzed diagnostic performance is summarized in Figure 18 and Supplementary Figure 15.

Chemiluminescent microparticle immunoassay

The analysis identified 13 published studies that used CMIA as a diagnostic technique for COVID-19. After analysis, only five studies [81,88,105,107,133] were selected. A total of 939 subjects were studied. Sensitivity ranged from 62.8 to 95.7%, with a median of 90.3%, and 95%CI (76.4, 96.4). Test for equality of sensitivities analysis showed: χ^2 = 51.58, df = 4, p-value = $1.69e^{-10}$. Specificity ranged from 95.3 to 99.7%, with a median of 98.8%, 95%CI (93.8, 99.8);), while the test for equality of specificities: χ^2 = 6.26, df = 4, p-value = 0.18. Also, a negative correlation between sensitivities and false positive rates is shown r = 0.487, 95%CI (–0.693, 0.958). In addition, results regarding LR+ {median 60.79, 95%CI (12.37, 476.78)}, LR− {median 0.10, 95%CI (0.04, 0.27)} and DOR {median 615.95, 95%CI (74.57, 4343.60)} are displayed. The diagnostic performance of the selected studies is summarized in Figure 19 and Supplementary Figure 16.

Fluorescence immunoassay

Three studies were selected using the FIA technique [121,134,135], in which a total of 829 subjects were studied. Sensitivity ranged from 38.0% to 92.6%, with a median of 64.4%, 95%CI (59.0, 73.0), while the test for equality of sensitivities presented a χ^2 = 49.92, df = 4, p-value = $3.75e^{-10}$. Specificity ranged from 97.1 to 99.5%, with a median of 99.0%, 95%CI (93.5, 99.9); the test for equality of specificities showed χ^2 = 4.12, df = 4, p-value = 0.39. A negative correlation between sensitivities and false positive rates is shown r = 0.282, 95%CI (–0.799, 0.932). Additionally, results regarding LR+ {median 77.43, 95%CI (5.56, 1275.84)}, LR− {median 0.35, 95%CI (0.28, 0.43)} and DOR {median 124.95, 95%CI (26.33, 2224.82)}. The analyzed diagnostic performance is summarized in Figure 20 and Supplementary Figure 17.

Other techniques

Regarding the NGS, MA, ELISA for IgG-IgM-IgA, ELISA for IgG-IgM / IgG-IgA, CLIA for IgG-IgM-IgA, CLIA for N protein, LFIA for S protein and ECLIA diagnostic techniques, one [89], zero, four [74,81,136,137], two [77,108], one [137], four [135,138–140], one [126],

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

and three [105,107,111] studies were selected, respectively. According to the established criteria, at least five studies were needed for the analysis with a value of $p < 0.05$. So, no analysis was developed regarding these diagnostic techniques.

Summary ROC curves (sROC)

Comparison of the diagnostic techniques data for COVID-19 (RT-PCR, RT-LAMP, CRISPR, ELISA IgG, ELISA IgM, ELISA IgA, ABN, BS, CLIA IgG, CLIA IgM, CLIA IgM-IgG, LFIA IgG, LFIA IgM, LFIA IgM-IgG, LFIA N protein, CMIA, and FIA) was performed through an sROC curve analysis (Figure 21), due to implicit or explicit alterations between studies and variation in the cut-off points of the test, differences in sensitivity and specificity may occur [141,142]. The area under the curve (AUC) calculated for the diagnostic techniques for COVID-19 is shown in Figure 21, showing better performance for ABN. Furthermore, when the AUC was limited to the observed false positive rates (FPR) (AUC_{FPR}) results revealed the relatively better performance of the ABN diagnostic test for COVID-19 (Figure 21).

Discussion

COVID-19 is a disease that has caused a devastating impact, leaving an experience for the new generations to take into consideration different factors that favor the emergence of infectious diseases [143]. The COVID-19 pandemic highlighted the weaknesses that exist in disease detection, alert, and response mechanisms. It demonstrated the need for a restart of the global health and health security system, as the world is highly interconnected, and a pandemic can break out in a matter of days [144]. The transmission of infectious diseases is mainly related to human movement, in the increase is related to transportation networks and globalization. In this context, the spread of pathogenic microorganisms, such as SARS-CoV-2, can be rapid and difficult its prevent and manage [145]. Furthermore, the ratio of asymptomatic people who give a positive result for COVID-19 varies between 8.44% and 39.00% [146], with the potential that asymptomatic carriers could be capable of transmitting COVID-19 during the incubation process without showing any symptoms or sign [147,148]. The viral load of SARS-CoV-2 decreases rapidly with the immune response; on the other hand, the generation of antibodies begins days after the onset of the infection, so to establish an adequate diagnosis, the start time of the possible infection should be considered. infection, taking into account that the sensitivity of molecular tests will decrease over time, but the sensitivity of serological tests will increase after several days of infection[149]. For these reasons, the accurate and timely identification of patients infected with COVID-19 plays an important role in the detection, diagnosis, follow-up, and surveillance of this pandemic [150,151]. However, most of the early diagnostic techniques developed for COVID-19 present limitations, such as sensitivity and/or specificity [152]. In addition, diagnostic tests required processing in laboratories with sophisticated materials, leading to a longer turnaround time and several days needed for results be available. Some of these hurdles were later perfected by newly developed assays that have better-defined analytical accuracy than earlier assays with better-defined analytical accuracy than earlier one[153,154].

SARS-CoV-2 is an RNA virus and, therefore, the different molecular tests available for detection of R; therefore, the different molecular tests available for detecting can be used

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

to identify the virus [155,156]. RNA of the virus must be transcribed into a DNA complement by reverse transcriptase to apply DNA detection methods [157]. Currently, the most widely used molecular method for the early detection of COVID-19 is RT-PCR; while other promising options, such as RT-LAMP and CRISPR have been developed [158]. RT-PCR is considered the gold standard molecular diagnostic test for COVID-19 worldwide due to its high specificity; however, limited access to kits and reagents, the use of expensive laboratory equipment, and the need for qualified personnel led to slow detection of the virus [159,160]. As well, it has been reported that the RT-PCR test can fail in suspected and confirmed patients with clinical implications. In this context, other clinical and molecular tests should also be considered in the diagnosis of COVID-19 [159,161]. On the other hand, it has been described that asymptomatic infected people have a few copies below the detection limit of the nucleic acid within the upper respiratory tract, causing false negatives in asymptomatic infected individuals, due to this the determination of asymptomatic infections with high specificity and sensitivity is a key point for managing the pandemic [162]. About these criteria, the analysis showed that there is no significant difference between molecular tests between RT-PCR and CRISPR, with a median sensitivity of 94.5, 94.4%, and specificity of 98.4, and 98.6% for RT-PCR. PCR, and CRISPR, respectively. However, when comparing AUC_{FPR}, CRISPR showed superior results, which can be explained partially explained by the difference in the number of studies evaluated and sample sizes. CRISPR-based COVID-19 diagnosis has advantages such as high detection speed (approximately 30 minutes), high sensitivity and accuracy, portability, and does not need specialized laboratory equipment [160]. Furthermore, RT-LAMP showed the highest specificity among the molecular tests with a median of 98.8% but the lowest sensitivity with a median of 91.9%. RT-LAMP has advantages over RT-PCR, such as amplification at a constant temperature, no thermocycler required, and a faster result, while maintaining similar sensitivity and specificity, which could make it more suitable than RT-PCR for monitoring a pandemic [163]. The molecular diagnosis makes it possible to identify people infected with SARS-CoV-2 one week before the onset of symptoms, while. At the same time, antibodies can only be detected ≥ 8 days after the onset of symptoms, so molecular diagnoses are essential for early diagnosis of COVID-19 [164,165]. When comparing data from molecular tests with serological tests for the diagnosis of COVID-19, molecular tests in general present a better performance, with AUC_{FPR} of 0.949, 0.936, 0.952 for RT-PCR, RT-LAMP, and CRISPR, respectively.

There are various serological tests to detect the antibody response caused by COVID-19. The main methods are ELISA, CLIA, LFIA, CMIA, FIA, and ANB [166–168]. It has been reported that serological assays have adequate sensitivity and specificity for the detection of SARS-CoV2, but this performance is related to the patient's convalescence, so understanding the kinetics of antibodies during SARS-CoV-2 infection. In this context, it is essential to establish the serological result for the diagnosis of the disease [168,169]. Data from ELISA, CLIA, LFIA, CMIA, and FIA-based serological tests show low sensitivity with a median less than or equal to 90% and high specificity with a median greater than or equal to 97%. Low sensitivity would produce false negative results since they cannot detect intrinsic immunological differences or immune responses between individuals, and it must be considered that in asymptomatic patients antibodies can be produced, still, their titers are not as high as those detected in symptomatic patients [170]. When SARS-

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

CoV-2 invades the human body and releases antigens, the immune system is activated to produce many specific antibodies (IgM/IgA/IgG), the host's immune cells produce IgM and IgA at an early stage of infection, while IgG at a late stage [171–173].

ELISA, CLIA, and LFIA diagnostic techniques were broken down according to the antibody they detected (IgG, IgM, IgA, and IgG-IgM). The detection of IgG by these tests generated the highest AUC_{FPR} demonstrating the higher performance of this antibody. This could be because IgM levels start to decrease at week 5 and almost disappear after week 7, while IgG levels persist beyond week 7, demonstrating the greater stability of IgG [174]. On the other hand, different structural proteins are anchored on the surface of the SARS-CoV-2 membrane, mainly spike (S) nucleocapsid (N), membrane (M), and envelope (E) [173,175]; N protein is a highly immunogenic protein and abundantly expressed during infection, so it can be useful for the diagnosis of COVID-19 [176]. In the data analysis of the LFIA technique, its performance was analyzed against the detection of detecting the N protein of SARS-COV-2, giving a median sensitivity and specificity of 74.7% and 99.4%, respectively. Besides, it should be noted that N protein has better stability than RNA, which can effectively compensate for the low sensitivity it shows [177]. Because many companies can generate serology tests, these tests can reach millions of people per day, which can help improve the detection of SARS-CoV-2, especially in countries with limited resources [177]. However, to obtain adequate sensitivity and specificity, it is recommended to combine clinical, molecular, and serological diagnostic tests [178].

It is worth noting that the diagnostic test that showed a higher performance for the detection of COVID-19, considering molecular and serological techniques, was the ANB, with a median of 95.6 and 99.5% for sensitivity and specificity, respectively; in addition, it obtained the highest AUC_{FPR} of 0.984. Neutralizing antibodies are produced weeks after infection and can protect cells from virus intrusion, protecting cells from virus intrusion and giving cells protective immunity [179]. ANBs are capable of quantitatively detecting neutralizing antibodies against SARS-CoV-2, making it possible to analyze the relationship between the level of neutralizing antibodies and the severity of the disease, and they can also predict the possibility of reinfection in patients with COVID-19 [179,180]. In general, neutralizing antibodies are measured by the plaque reduction neutralization test (PRNT), which is currently the gold standard for serological tests and the determination of immune protection [181].

Molecular techniques such as NGS allow the investigation of the genetic composition of SARS-CoV-2, allowing its detection [182], and MA has been used for genotyping and the determination of agents that cause diseases such as SARS-CoV-2 [183,184]. Furthermore, ECLIA serological-based diagnostic technique is a valid detection method for COVID-19 [185,186]; however, the number of selected studies of these techniques prevented their inclusion in the meta-analysis, which needs at least five studies for analysis with a p-value lower than 0.05 [142]. In a search of individual MeSH terms for "COVID-19", "Sensitivity and specificity", "Next generation sequencing", "Microarray Analysis", and "Immunoassay" showed 195,931, 641,415, 49,966, 95,596, and 2,150 studies, respectively, while linking them only found 16, 3 and 367, correspondingly. For what should be considered as work limitations, common errors associated with systematic review and meta-analysis studies, such as study location and selection, missing important information about the results, inappropriate subgroup analysis, conflicts with new

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

experimental data, and duplicate publication [187]. In addition, various problems, such as heterogeneity of study groups, clinical settings, and measures of diagnostic performance, were established in the present study, while. In contrast, biased estimates of diagnostic test performance could be overestimated [142,188]. It should be considered that to obtain adequate sensitivity and specificity, it is recommended to combine clinical, molecular, and serological diagnostic tests [178]; however, applying all these diagnostic techniques simultaneously is a barrier for countries with populations living in poverty, clearly observing the inequity in health that exists, which is a problem for the control of any pandemic [189].

Conclusions

The precise detection of new infectious agents such as SARS-CoV-2 is important for the proper management of properly managing a pandemic to stop its spread. The present study evaluated the performance of various diagnostic techniques reported for COVID-19, where molecular tests (RT-PCR, RT-LAMP, and CRISPR) presented a better performance in terms of sensitivity and specificity as compared to serological tests (ELISA, CLIA, LFIA, CMIA, and FIA) for the detection of SARS-CoV-2. In addition, serological tests were shown to have high specificity, mainly when IgG was detected, but relatively low sensitivity. It should be noted that the ANB-based diagnostic technique reported the best performance among all the methods evaluated, demonstrating its potential for the diagnosis of SARS-CoV-2 infection. However, further optimization of testing, in general, is still required, and emphasis should be placed on the development of rapid, scalable, and high-precision assays for the control of future outbreaks of SARS-CoV-2 and other infectious agents that may occur in the future.

Author Contributions: Conceptualization: M.A.C.-P. and M.A.C.-F.; data curation: M.A.C.-P., J. J. V. A., K. C. M., and L. D. G. M.; formal analysis: M.A.C.-P. and M.A.C.-F.; funding acquisition: M.A.C.-P. and M.A.C.-F.; investigation: L. D. G. M., A.S.G., R.C.G., R. A. M.D., and E.A.F.C.; methodology: M.A.C.-P. and M.A.C.-F.; writing—review and editing: A.S.G., R.C.G., R. A. M.D., E.A.F.C., and M.A.C.-F. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by Universidad Catolica de Santa Maria (grants 27574-R-2020, and 28048-R-2021).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Data Availability Statement
Not applicable.

Acknowledgments
Not applicable.

Conflicts of Interest
The authors declare no conflict of interest.

Abbreviations
The following abbreviations are used in this study.

ACE2	Angiotensin-converting enzyme 2
ANB	Antiviral neutralization bioassay
AUC	Area Under the Curve
AUC_{FPR}	Area Under the Curve Restricted to The False Positive Rates
BS	Biosensors
CI	Confidence interval
CLIA	Chemiluminescence immunoassay
CMIA	Chemiluminescent microparticle immunoassay
COVID-19	Coronavirus disease
CRISPR	Clustered regularly interspaced short palindromic repeats
DOR	Diagnostic Likelihood Ratio
ECLIA	Electrochemiluminescence immunoassay
ELISA	Enzyme-Linked Immunosorbent Assay
FIA	Fluorescence immunoassay
FN	False negatives
FP	False positives
IgA	Immunoglobulin A
IgG	Immunoglobulin G
IgM	Immunoglobulin M
INPLASY	International Platform of Registered Systematic Review and Meta-analysis Protocols
LFIA	Lateral flow immunoassay
LR−	Negative Likelihood Ratio
LR+	Positive Likelihood Ratio
MA	Microarrays
MeSH	Medical Subject Headings
NCBI	National Center for Biotechnology Information
NGS	Next-generation sequencing
PRISMA	Preferred Reporting Items for Systematic Reviews and Meta-Analyses
ROC	Receiver Operating Characteristics
RT-LAMP	Reverse transcriptase loop-mediated isothermal amplification
RT-PCR	Reverse transcription–polymerase chain reaction
SARS-CoV-2	Severe acute respiratory syndrome coronavirus 2
Se	Sensibility
Sp	Specificity
sROC	Summary Receiver Operating Characteristics
TN	True negatives
TP	True positives

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

WHO	World Health Organization

References

1. Goh, G.K.-M.; Dunker, A.K.; Foster, J.A.; Uversky, V.N. Computational, Experimental, and Clinical Evidence of a Specific but Peculiar Evolutionary Nature of (COVID-19) SARS-CoV-2. *J Proteome Res* **2022**, *21*, 874–890, doi:10.1021/acs.jproteome.2c00001.

2. Labib, S.M.; Browning, M.H.E.M.; Rigolon, A.; Helbich, M.; James, P. Nature's Contributions in Coping with a Pandemic in the 21st Century: A Narrative Review of Evidence during COVID-19. *Science of The Total Environment* **2022**, *833*, 155095, doi:10.1016/j.scitotenv.2022.155095.

3. Stiti, M.; Castanet, G.; Corber, A.; Alden, M.; Berrocal, E. Transition from Saliva Droplets to Solid Aerosols in the Context of COVID-19 Spreading. *Environ Res* **2022**, *204*, 112072, doi:10.1016/j.envres.2021.112072.

4. Lin, Y.; Sun, J.; Cao, X.; Wang, X.; Chen, X.; Xu, H.; Zhao, J.; Fu, Y.-X.; Peng, H. Non-Adjuvanted Interferon-Armed RBD Protein Nasal Drops Protect Airway Infection from SARS-CoV-2. *Cell Discov* **2022**, *8*, 43, doi:10.1038/s41421-022-00411-4.

5. World Health Organization WHO Coronavirus (COVID-19) Dashboard Available online: https://covid19.who.int/.

6. Xu, H.; Xie, C.; Li, P.; Ji, Z.; Sun, J.; Hu, B.; Li, X.; Fang, M. Demographic, Virological Characteristics and Prognosis of Asymptomatic COVID-19 Patients in South China. *Front Med (Lausanne)* **2022**, *9*, 830942, doi:10.3389/fmed.2022.830942.

7. Sah, P.; Fitzpatrick, M.C.; Zimmer, C.F.; Abdollahi, E.; Juden-Kelly, L.; Moghadas, S.M.; Singer, B.H.; Galvani, A.P. Asymptomatic SARS-CoV-2 Infection: A Systematic Review and Meta-Analysis. *Proceedings of the National Academy of Sciences* **2021**, *118*, e2109229118, doi:10.1073/pnas.2109229118.

8. Ranjan, P.; Singhal, A.; Yadav, S.; Kumar, N.; Murali, S.; Sanghi, S.K.; Khan, R. Rapid Diagnosis of SARS-CoV-2 Using Potential Point-of-Care Electrochemical Immunosensor: Toward the Future Prospects. *Int Rev Immunol* **2021**, *40*, 126–142, doi:10.1080/08830185.2021.1872566.

9. Bartsch, S.M.; Ferguson, M.C.; McKinnell, J.A.; O'Shea, K.J.; Wedlock, P.T.; Siegmund, S.S.; Lee, B.Y. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. *Health Aff* **2020**, *39*, 927–935, doi:10.1377/hlthaff.2020.00426.

10. Umakanthan, S.; Chattu, V.K.; Ranade, A. V; Das, D.; Basavarajegowda, A.; Bukelo, M. A Rapid Review of Recent Advances in Diagnosis, Treatment and Vaccination for COVID-19. *AIMS Public Health* **2021**, *8*, 137–153, doi:10.3934/publichealth.2021011.

11. SeyedAlinaghi, S.; Afsahi, A.; MohsseniPour, M.; Behnezhad, F.; Salehi, M.; Barzegary, A.; Mirzapour, P.; Mehraeen, E.; Dadras, O. Late Complications of COVID-19; a Systematic Review of Current Evidence. *Arch Acad Emerg Med* **2021**, *9*, e14, doi:10.22037/aaem.v9i1.1058.

12. da Rosa Mesquita, R.; Francelino Silva Junior, L.C.; Santos Santana, F.M.; Farias de Oliveira, T.; Campos Alcântara, R.; Monteiro Arnozo, G.; Rodrigues da Silva Filho, E.; Galdino dos Santos, A.G.;

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Oliveira da Cunha, E.J.; Salgueiro de Aquino, S.H.; et al. Clinical Manifestations of COVID-19 in the General Population: Systematic Review. *Wien Klin Wochenschr* **2021**, *133*, 377–382, doi:10.1007/s00508-020-01760-4.

13. Eskian, M.; Rezaei, N. Clinical Manifestations of COVID-19. In *Coronavirus Disease - COVID-19*; Springer, 2021; pp. 179–196.

14. Badraoui, R.; Alrashedi, M.M.; El-May, M.V.; Bardakci, F. Acute Respiratory Distress Syndrome: A Life Threatening Associated Complication of SARS-CoV-2 Infection Inducing COVID-19. *J Biomol Struct Dyn* **2021**, *39*, 6842–6851, doi:10.1080/07391102.2020.1803139.

15. Ball, L.; Silva, P.L.; Giacobbe, D.R.; Bassetti, M.; Zubieta-Calleja, G.R.; Rocco, P.R.M.; Pelosi, P. Understanding the Pathophysiology of Typical Acute Respiratory Distress Syndrome and Severe COVID-19. *Expert Rev Respir Med* **2022**, *16*, 437–446, doi:10.1080/17476348.2022.2057300.

16. Rajput, A.; Sajid, M.; Tanvi; Shekhar, C.; Aggarwal, R. Optimal Control Strategies on COVID-19 Infection to Bolster the Efficacy of Vaccination in India. *Sci Rep* **2021**, *11*, 20124, doi:10.1038/s41598-021-99088-0.

17. Desai, A.D.; Lavelle, M.; Boursiquot, B.C.; Wan, E.Y. Long-Term Complications of COVID-19. *American Journal of Physiology-Cell Physiology* **2022**, *322*, C1–C11, doi:10.1152/ajpcell.00375.2021.

18. Nguyen, K.H.; Nguyen, K.; Corlin, L.; Allen, J.D.; Chung, M. Changes in COVID-19 Vaccination Receipt and Intention to Vaccinate by Socioeconomic Characteristics and Geographic Area, United States, January 6 – March 29, 2021. *Ann Med* **2021**, *53*, 1419–1428, doi:10.1080/07853890.2021.1957998.

19. Evans, N.G.; Berger, Z.D.; Phelan, A.L.; Silverman, R.D. Covid-19, Equity, and Inclusiveness. *BMJ* **2021**, *373*, n1631, doi:10.1136/bmj.n1631.

20. Christie, A.; Mbaeyi, S.A.; Walensky, R.P. CDC Interim Recommendations for Fully Vaccinated People. *JAMA* **2021**, *325*, 1501, doi:10.1001/jama.2021.4367.

21. Hanna, G.; Bankler, S.; Schandl, A.; Roël, M.; Hedman, A.; Andersson Franko, M.; Lyngå, P.; Geborek, A.; Joelsson-Alm, E.; Söderberg, M.; et al. The Role of Ventilatory Support for Long-term Outcomes after Critical Infection with COVID-19: A Prospective Cohort Study. *Clin Respir J* **2022**, *16*, 63–71, doi:10.1111/crj.13453.

22. Chen, B.; Liu, M.; Huang, C. Current Diagnostic and Therapeutic Strategies for COVID-19. *J Pharm Anal* **2021**, *11*, 129–137, doi:10.1016/j.jpha.2020.12.001.

23. dos Santos, M.; Ferreira, A.V.F.; da Silva, J.O.; Nogueira, L.M.; Machado, J.M.; Francisco, M.F.C.; da Paz, M.C.; Giunchetti, R.C.; Galdino, A.S. Patents Related to Pathogenic Human Coronaviruses. *Recent Pat Biotechnol* **2021**, *15*, 12–24, doi:10.2174/1872208315666210127085404.

24. Udugama, B.; Kadhiresan, P.; Kozlowski, H.N.; Malekjahani, A.; Osborne, M.; Li, V.Y.C.; Chen, H.; Mubareka, S.; Gubbay, J.B.; Chan, W.C.W. Diagnosing COVID-19: The Disease and Tools for Detection. *ACS Nano* **2020**, *14*, 3822–3835, doi:10.1021/acsnano.0c02624.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

25. Venter, M.; Richter, K. Towards Effective Diagnostic Assays for COVID-19: A Review. *J Clin Pathol* **2020**, *73*, 370–377, doi:10.1136/jclinpath-2020-206685.

26. Tahamtan, A.; Ardebili, A. Real-Time RT-PCR in COVID-19 Detection: Issues Affecting the Results. *Expert Rev Mol Diagn* **2020**, *20*, 453–454, doi:10.1080/14737159.2020.1757437.

27. Dolatshahi, Z.; Nargesi, S.; Sadeghifar, J.; Mezginejad, F.; Jafari, A.; Bazyar, M.; Ghafourian, S.; Sani'ee, N. Economic Evaluation of Laboratory Diagnostic Test Types in Covid-19 Epidemic: A Systematic Review. *International Journal of Surgery* **2022**, *105*, 106820, doi:10.1016/j.ijsu.2022.106820.

28. Spick, M.; Lewis, H.M.; Wilde, M.J.; Hopley, C.; Huggett, J.; Bailey, M.J. Systematic Review with Meta-Analysis of Diagnostic Test Accuracy for COVID-19 by Mass Spectrometry. *Metabolism* **2022**, *126*, 154922, doi:10.1016/j.metabol.2021.154922.

29. Peroni, L.A.; Toscaro, J.M.; Canateli, C.; Tonoli, C.C.C.; de Olivera, R.R.; Benedetti, C.E.; Coimbra, L.D.; Pereira, A.B.; Marques, R.E.; Proença-Modena, J.L.; et al. Serological Testing for COVID-19, Immunological Surveillance, and Exploration of Protective Antibodies. *Front Immunol* **2021**, *12*, 635701, doi:10.3389/fimmu.2021.635701.

30. Makoah, N.A.; Tipih, T.; Litabe, M.M.; Brink, M.; Sempa, J.B.; Goedhals, D.; Burt, F.J. A Systematic Review and Meta-Analysis of the Sensitivity of Antibody Tests for the Laboratory Confirmation of COVID-19. *Future Virol* **2022**, *17*, 119–139, doi:10.2217/fvl-2021-0211.

31. Guo, J.; Ge, J.; Guo, Y. Recent Advances in Methods for the Diagnosis of Corona Virus Disease 2019. *J Clin Lab Anal* **2022**, *36*, e24178, doi:10.1002/jcla.24178.

32. Nuccetelli, M.; Pieri, M.; Gisone, F.; Bernardini, S. Combined Anti-SARS-CoV-2 IgA, IgG, and IgM Detection as a Better Strategy to Prevent Second Infection Spreading Waves. *Immunol Invest* **2022**, *51*, 233–245, doi:10.1080/08820139.2020.1823407.

33. Peeling, R.W.; Olliaro, P.L.; Boeras, D.I.; Fongwen, N. Scaling up COVID-19 Rapid Antigen Tests: Promises and Challenges. *Lancet Infect Dis* **2021**, *21*, e290–e295, doi:10.1016/S1473-3099(21)00048-7.

34. Khalid, M.F.; Selvam, K.; Jeffry, A.J.N.; Salmi, M.F.; Najib, M.A.; Norhayati, M.N.; Aziah, I. Performance of Rapid Antigen Tests for COVID-19 Diagnosis: A Systematic Review and Meta-Analysis. *Diagnostics* **2022**, *12*, 110, doi:10.3390/diagnostics12010110.

35. Yamayoshi, S.; Sakai-Tagawa, Y.; Koga, M.; Akasaka, O.; Nakachi, I.; Koh, H.; Maeda, K.; Adachi, E.; Saito, M.; Nagai, H.; et al. Comparison of Rapid Antigen Tests for COVID-19. *Viruses* **2020**, *12*, 1420, doi:10.3390/v12121420.

36. Page, M.J.; Moher, D.; Bossuyt, P.M.; Boutron, I.; Hoffmann, T.C.; Mulrow, C.D.; Shamseer, L.; Tetzlaff, J.M.; Akl, E.A.; Brennan, S.E.; et al. PRISMA 2020 Explanation and Elaboration: Updated Guidance and Exemplars for Reporting Systematic Reviews. *BMJ* **2021**, *372*, n160, doi:10.1136/bmj.n160.

37. Fiorini, N.; Leaman, R.; Lipman, D.J.; Lu, Z. How User Intelligence Is Improving PubMed. *Nat Biotechnol* **2018**, *36*, 937–945, doi:10.1038/nbt.4267.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

38. van Eck, N.J.; Waltman, L. Citation-Based Clustering of Publications Using CitNetExplorer and VOSviewer. *Scientometrics* **2017**, *111*, 1053–1070, doi:10.1007/s11192-017-2300-7.

39. Lee, J.; Kim, K.W.; Choi, S.H.; Huh, J.; Park, S.H. Systematic Review and Meta-Analysis of Studies Evaluating Diagnostic Test Accuracy: A Practical Review for Clinical Researchers–Part II. Statistical Methods of Meta-Analysis. *Korean J Radiol* **2015**, *16*, 1188–1196, doi:10.3348/kjr.2015.16.6.1188.

40. Shim, S.R.; Kim, S.-J.; Lee, J. Diagnostic Test Accuracy: Application and Practice Using R Software. *Epidemiol Health* **2019**, *41*, e2019007, doi:10.4178/epih.e2019007.

41. Shreffler, J.; Huecker, M.R. Diagnostic Testing Accuracy: Sensitivity, Specificity, Predictive Values and Likelihood Ratios. In *StatPearls [Internet]*; StatPearls Publishing, 2022.

42. Huang, Y.; Yin, J.; Samawi, H. Methods Improving the Estimate of Diagnostic Odds Ratio. *Commun Stat Simul Comput* **2018**, *47*, 353–366, doi:10.1080/03610918.2016.1157183.

43. Reitsma, J.B.; Glas, A.S.; Rutjes, A.W.S.; Scholten, R.J.P.M.; Bossuyt, P.M.; Zwinderman, A.H. Bivariate Analysis of Sensitivity and Specificity Produces Informative Summary Measures in Diagnostic Reviews. *J Clin Epidemiol* **2005**, *58*, 982–990, doi:10.1016/j.jclinepi.2005.02.022.

44. Visseaux, B.; Collin, G.; Houhou-Fidouh, N.; Le Hingrat, Q.; Ferré, V.M.; Damond, F.; Ichou, H.; Descamps, D.; Charpentier, C. Evaluation of Three Extraction-Free SARS-CoV-2 RT-PCR Assays: A Feasible Alternative Approach with Low Technical Requirements. *J Virol Methods* **2021**, *291*, 114086, doi:10.1016/j.jviromet.2021.114086.

45. Ghoshal, U.; Garg, A.; Vasanth, S.; Arya, A.K.; Pandey, A.; Tejan, N.; Patel, V.; Singh, V.P. Assessing a Chip Based Rapid RTPCR Test for SARS CoV-2 Detection (TrueNat Assay): A Diagnostic Accuracy Study. *PLoS One* **2021**, *16*, e0257834, doi:10.1371/journal.pone.0257834.

46. Gadkar, V.J.; Goldfarb, D.M.; Young, V.; Watson, N.; Al-Rawahi, G.N.; Srigley, J.A.; Tilley, P. Development and Validation of a New Triplex Real-Time Quantitative Reverse Transcriptase-PCR Assay for the Clinical Detection of SARS-CoV-2. *Mol Cell Probes* **2021**, *58*, 101744, doi:10.1016/j.mcp.2021.101744.

47. Hernández, C.; Florez, C.; Castañeda, S.; Ballesteros, N.; Martínez, D.; Castillo, A.; Muñoz, M.; Gomez, S.; Rico, A.; Pardo, L.; et al. Evaluation of the Diagnostic Performance of Nine Commercial RT-PCR Kits for the Detection of SARS-CoV-2 in Colombia. *J Med Virol* **2021**, *93*, 5618–5622, doi:10.1002/jmv.27051.

48. Fitoussi, F.; Dupont, R.; Tonen-Wolyec, S.; Bélec, L. Performances of the VitaPCR™ SARS-CoV-2 Assay during the Second Wave of the COVID-19 Epidemic in France. *J Med Virol* **2021**, *93*, 4351–4357, doi:10.1002/jmv.26950.

49. Castineiras, T.M.P.P.; Nascimento, É.R.D.S.; Faffe, D.S.; Galliez, R.M.; Mariani, D.; Leitão, I. de C.; de Melo, M.G.M.; Ferreira, O.C.; Tanuri, A.; UFRJ COVID-19 Working group Performance of an Alternative RT-PCR Procedure Using Residual Sample from the Panbio™ Ag COVID-19 Test. *Braz J Infect Dis* **2021**, *25*, 101630, doi:10.1016/j.bjid.2021.101630.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

50. Zowawi, H.M.; Alenazi, T.H.; AlOmaim, W.S.; Wazzan, A.; Alsufayan, A.; Hasanain, R.A.; Aldibasi, O.S.; Althawadi, S.; Altamimi, S.A.; Mutabagani, M.; et al. Portable RT-PCR System: A Rapid and Scalable Diagnostic Tool for COVID-19 Testing. *J Clin Microbiol* **2021**, *59*, e03004-20, doi:10.1128/JCM.03004-20.

51. Altamimi, A.M.; Obeid, D.A.; Alaifan, T.A.; Taha, M.T.; Alhothali, M.T.; Alzahrani, F.A.; Albarrag, A.M. Assessment of 12 Qualitative RT-PCR Commercial Kits for the Detection of SARS-CoV-2. *J Med Virol* **2021**, *93*, 3219–3226, doi:10.1002/jmv.26900.

52. Al Suwaidi, H.; Senok, A.; Varghese, R.; Deesi, Z.; Khansaheb, H.; Pokasirakath, S.; Chacko, B.; Abufara, I.; Loney, T.; Alsheikh-Ali, A. Saliva for Molecular Detection of SARS-CoV-2 in School-Age Children. *Clin Microbiol Infect* **2021**, *27*, 1330–1335, doi:10.1016/j.cmi.2021.02.009.

53. Bustin, S.; Coward, A.; Sadler, G.; Teare, L.; Nolan, T. CoV2-ID, a MIQE-Compliant Sub-20-Min 5-Plex RT-PCR Assay Targeting SARS-CoV-2 for the Diagnosis of COVID-19. *Sci Rep* **2020**, *10*, 22214, doi:10.1038/s41598-020-79233-x.

54. Rajh, E.; Šket, T.; Praznik, A.; Sušjan, P.; Šmid, A.; Urbančič, D.; Mlinarič-Raščan, I.; Kogovšek, P.; Demšar, T.; Milavec, M.; et al. Robust Saliva-Based RNA Extraction-Free One-Step Nucleic Acid Amplification Test for Mass SARS-CoV-2 Monitoring. *Molecules* **2021**, *26*, 6617, doi:10.3390/molecules26216617.

55. Abdullah, M.; Sudrajat, D.G.; Muzellina, V.N.; Kurniawan, J.; Rizka, A.; Utari, A.P.; Pribadi, R.R.; Idrus, M.F.; Yusra, Y.; Meilany, S.; et al. The Value of Anal Swab RT-PCR for COVID-19 Diagnosis in Adult Indonesian Patients. *BMJ Open Gastroenterol* **2021**, *8*, e000590, doi:10.1136/bmjgast-2020-000590.

56. Singh, J.; Yadav, A.K.; Pakhare, A.; Kulkarni, P.; Lokhande, L.; Soni, P.; Dadheech, M.; Gupta, P.; Masarkar, N.; Maurya, A.K.; et al. Comparative Analysis of the Diagnostic Performance of Five Commercial COVID-19 QRT PCR Kits Used in India. *Sci Rep* **2021**, *11*, 22013, doi:10.1038/s41598-021-00852-z.

57. Chang, P.-L.; Lin, C.-Y.; Chen, C.-P.; Lin, Y.-C.; Hu, H.-C.; Cheng, S.-H.; Cheng, C.-Y. Clinical Validation of an Automated Reverse Transcription-Insulated Isothermal PCR Assay for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2. *Journal of microbiology, immunology, and infection* **2021**, *54*, 522–526, doi:10.1016/j.jmii.2021.01.005.

58. Visseaux, B.; Le Hingrat, Q.; Collin, G.; Ferré, V.; Storto, A.; Ichou, H.; Bouzid, D.; Poey, N.; de Montmollin, E.; Descamps, D.; et al. Evaluation of the RealStar® SARS-CoV-2 RT-PCR Kit RUO Performances and Limit of Detection. *J Clin Virol* **2020**, *129*, 104520, doi:10.1016/j.jcv.2020.104520.

59. Rödel, J.; Egerer, R.; Suleyman, A.; Sommer-Schmid, B.; Baier, M.; Henke, A.; Edel, B.; Löffler, B. Use of the Variplex™ SARS-CoV-2 RT-LAMP as a Rapid Molecular Assay to Complement RT-PCR for COVID-19 Diagnosis. *J Clin Virol* **2020**, *132*, 104616, doi:10.1016/j.jcv.2020.104616.

60. Hu, X.; Deng, Q.; Li, J.; Chen, J.; Wang, Z.; Zhang, X.; Fang, Z.; Li, H.; Zhao, Y.; Yu, P.; et al. Development and Clinical Application of a Rapid and Sensitive Loop-Mediated Isothermal

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Amplification Test for SARS-CoV-2 Infection. *mSphere* **2020**, *5*, e00808-20, doi:10.1128/mSphere.00808-20.

61. Lee, J.Y.H.; Best, N.; McAuley, J.; Porter, J.L.; Seemann, T.; Schultz, M.B.; Sait, M.; Orlando, N.; Mercoulia, K.; Ballard, S.A.; et al. Validation of a Single-Step, Single-Tube Reverse Transcription Loop-Mediated Isothermal Amplification Assay for Rapid Detection of SARS-CoV-2 RNA. *J Med Microbiol* **2020**, *69*, 1169–1178, doi:10.1099/jmm.0.001238.

62. Jiang, M.; Pan, W.; Arasthfer, A.; Fang, W.; Ling, L.; Fang, H.; Daneshnia, F.; Yu, J.; Liao, W.; Pei, H.; et al. Development and Validation of a Rapid, Single-Step Reverse Transcriptase Loop-Mediated Isothermal Amplification (RT-LAMP) System Potentially to Be Used for Reliable and High-Throughput Screening of COVID-19. *Front Cell Infect Microbiol* **2020**, *10*, 331, doi:10.3389/fcimb.2020.00331.

63. Dao Thi, V.L.; Herbst, K.; Boerner, K.; Meurer, M.; Kremer, L.P.; Kirrmaier, D.; Freistaedter, A.; Papagiannidis, D.; Galmozzi, C.; Stanifer, M.L.; et al. A Colorimetric RT-LAMP Assay and LAMP-Sequencing for Detecting SARS-CoV-2 RNA in Clinical Samples. *Sci Transl Med* **2020**, *12*, eabc7075, doi:10.1126/scitranslmed.abc7075.

64. Lu, R.; Wu, X.; Wan, Z.; Li, Y.; Jin, X.; Zhang, C. A Novel Reverse Transcription Loop-Mediated Isothermal Amplification Method for Rapid Detection of SARS-CoV-2. *Int J Mol Sci* **2020**, *21*, 2826, doi:10.3390/ijms21082826.

65. Schmidt, J.; Berghaus, S.; Blessing, F.; Wenzel, F.; Herbeck, H.; Blessing, J.; Schierack, P.; Rödiger, S.; Roggenbuck, D. A Semi-Automated, Isolation-Free, High-Throughput SARS-CoV-2 Reverse Transcriptase (RT) Loop-Mediated Isothermal Amplification (LAMP) Test. *Sci Rep* **2021**, *11*, 21385, doi:10.1038/s41598-021-00827-0.

66. Chen, Y.; Shi, Y.; Chen, Y.; Yang, Z.; Wu, H.; Zhou, Z.; Li, J.; Ping, J.; He, L.; Shen, H.; et al. Contamination-Free Visual Detection of SARS-CoV-2 with CRISPR/Cas12a: A Promising Method in the Point-of-Care Detection. *Biosens Bioelectron* **2020**, *169*, 112642, doi:10.1016/j.bios.2020.112642.

67. Hou, T.; Zeng, W.; Yang, M.; Chen, W.; Ren, L.; Ai, J.; Wu, J.; Liao, Y.; Gou, X.; Li, Y.; et al. Development and Evaluation of a Rapid CRISPR-Based Diagnostic for COVID-19. *PLoS Pathog* **2020**, *16*, e1008705, doi:10.1371/journal.ppat.1008705.

68. Xiong, E.; Jiang, L.; Tian, T.; Hu, M.; Yue, H.; Huang, M.; Lin, W.; Jiang, Y.; Zhu, D.; Zhou, X. Simultaneous Dual-Gene Diagnosis of SARS-CoV-2 Based on CRISPR/Cas9-Mediated Lateral Flow Assay. *Angew Chem Int Ed Engl* **2021**, *60*, 5307–5315, doi:10.1002/anie.202014506.

69. Li, S.; Huang, J.; Ren, L.; Jiang, W.; Wang, M.; Zhuang, L.; Zheng, Q.; Yang, R.; Zeng, Y.; Luu, L.D.W.; et al. A One-Step, One-Pot CRISPR Nucleic Acid Detection Platform (CRISPR-Top): Application for the Diagnosis of COVID-19. *Talanta* **2021**, *233*, 122591, doi:10.1016/j.talanta.2021.122591.

70. Curti, L.A.; Primost, I.; Valla, S.; Ibañez Alegre, D.; Olguin Perglione, C.; Repizo, G.D.; Lara, J.; Parcerisa, I.; Palacios, A.; Llases, M.E.; et al. Evaluation of a Lyophilized CRISPR-Cas12 Assay for a Sensitive, Specific, and Rapid Detection of SARS-CoV-2. *Viruses* **2021**, *13*, 420, doi:10.3390/v13030420.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

71. Nimsamer, P.; Mayuramart, O.; Rattanaburi, S.; Chantaravisoot, N.; Saengchoowong, S.; Puenpa, J.; Poovorawan, Y.; Payungporn, S. Comparative Performance of CRISPR-Cas12a Assays for SARS-CoV-2 Detection Tested with RNA Extracted from Clinical Specimens. *J Virol Methods* **2021**, *290*, 114092, doi:10.1016/j.jviromet.2021.114092.

72. Mayuramart, O.; Nimsamer, P.; Rattanaburi, S.; Chantaravisoot, N.; Khongnomnan, K.; Chansaenroj, J.; Puenpa, J.; Suntronwong, N.; Vichaiwattana, P.; Poovorawan, Y.; et al. Detection of Severe Acute Respiratory Syndrome Coronavirus 2 and Influenza Viruses Based on CRISPR-Cas12a. *Experimental biology and medicine (Maywood)* **2021**, *246*, 400–405, doi:10.1177/1535370220963793.

73. Sapkal, G.; Shete-Aich, A.; Jain, R.; Yadav, P.D.; Sarkale, P.; Lakra, R.; Baradkar, S.; Deshpande, G.R.; Mali, D.; Tilekar, B.N.; et al. Development of Indigenous IgG ELISA for the Detection of Anti-SARS-CoV-2 IgG. *Indian J Med Res* **2020**, *151*, 444–449, doi:10.4103/ijmr.IJMR_2232_20.

74. Tré-Hardy, M.; Wilmet, A.; Beukinga, I.; Favresse, J.; Dogné, J.-M.; Douxfils, J.; Blairon, L. Analytical and Clinical Validation of an ELISA for Specific SARS-CoV-2 IgG, IgA, and IgM Antibodies. *J Med Virol* **2021**, *93*, 803–811, doi:10.1002/jmv.26303.

75. Serrano, M.M.; Rodríguez, D.N.; Palop, N.T.; Arenas, R.O.; Córdoba, M.M.; Mochón, M.D.O.; Cardona, C.G. Comparison of Commercial Lateral Flow Immunoassays and ELISA for SARS-CoV-2 Antibody Detection. *Journal of clinical virology* **2020**, *129*, 104529, doi:10.1016/j.jcv.2020.104529.

76. Krüttgen, A.; Cornelissen, C.G.; Dreher, M.; Hornef, M.; Imöhl, M.; Kleines, M. Comparison of Four New Commercial Serologic Assays for Determination of SARS-CoV-2 IgG. *Journal of clinical virology* **2020**, *128*, 104394, doi:10.1016/j.jcv.2020.104394.

77. Montesinos, I.; Gruson, D.; Kabamba, B.; Dahma, H.; Van den Wijngaert, S.; Reza, S.; Carbone, V.; Vandenberg, O.; Gulbis, B.; Wolff, F.; et al. Evaluation of Two Automated and Three Rapid Lateral Flow Immunoassays for the Detection of Anti-SARS-CoV-2 Antibodies. *Journal of clinical virology* **2020**, *128*, 104413, doi:10.1016/j.jcv.2020.104413.

78. Krüttgen, A.; Cornelissen, C.G.; Dreher, M.; Hornef, M.W.; Imöhl, M.; Kleines, M. Determination of SARS-CoV-2 Antibodies with Assays from Diasorin, Roche and IDvet. *J Virol Methods* **2021**, *287*, 113978, doi:10.1016/j.jviromet.2020.113978.

79. Coste, A.T.; Jaton, K.; Papadimitriou-Olivgeris, M.; Greub, G.; Croxatto, A. Comparison of SARS-CoV-2 Serological Tests with Different Antigen Targets. *Journal of clinical virology* **2021**, *134*, 104690, doi:10.1016/j.jcv.2020.104690.

80. Mutantu, P.N.; Ngwe Tun, M.M.; Nabeshima, T.; Yu, F.; Mukadi, P.K.; Tanaka, T.; Tashiro, M.; Fujita, A.; Kanie, N.; Oshiro, R.; et al. Development and Evaluation of Quantitative Immunoglobulin G Enzyme-Linked Immunosorbent Assay for the Diagnosis of Coronavirus Disease 2019 Using Truncated Recombinant Nucleocapsid Protein as Assay Antigen. *Int J Environ Res Public Health* **2021**, *18*, 9630, doi:10.3390/ijerph18189630.

81. Barchuk, A.; Shirokov, D.; Sergeeva, M.; Tursun Zade, R.; Dudkina, O.; Tychkova, V.; Barabanova, L.; Skougarevskiy, D.; Danilenko, D. Evaluation of the Performance of SARS--CoV--2 Antibody

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Assays for a Longitudinal Population-Based Study of COVID--19 Spread in St. Petersburg, Russia. *J Med Virol* **2021**, *93*, 5846–5852, doi:10.1002/jmv.27126.

82. Sil, B.K.; Jahan, N.; Haq, M.A.; Oishee, M.J.; Ali, T.; Khandker, S.S.; Kobatake, E.; Mie, M.; Khondoker, M.U.; Jamiruddin, M.R.; et al. Development and Performance Evaluation of a Rapid In-House ELISA for Retrospective Serosurveillance of SARS-CoV-2. *PLoS One* **2021**, *16*, e0246346, doi:10.1371/journal.pone.0246346.

83. Tozetto-Mendoza, T.R.; Kanunfre, K.A.; Vilas-Boas, L.S.; Sanchez Espinoza, E.P.; Paião, H.G.O.; Rocha, M.C.; de Paula, A.V.; de Oliveira, M.S.; Zampelli, D.B.; Vieira, J.M.; et al. Nucleoprotein-Based ELISA for Detection of SARS-COV-2 IgG Antibodies: Could an Old Assay Be Suitable for Serodiagnosis of the New Coronavirus? *J Virol Methods* **2021**, *290*, 114064, doi:10.1016/j.jviromet.2021.114064.

84. Zhou, C.; Bu, G.; Sun, Y.; Ren, C.; Qu, M.; Gao, Y.; Zhu, Y.; Wang, L.; Sun, L.; Liu, Y. Evaluation of Serum IgM and IgG Antibodies in COVID-19 Patients by Enzyme Linked Immunosorbent Assay. *J Med Virol* **2021**, *93*, 2857–2866, doi:10.1002/jmv.26741.

85. Cramer, A.; Goodman, N.; Cross, T.; Gant, V.; Dziadzio, M. Analytical Evaluation and Critical Appraisal of Early Commercial SARS-CoV-2 Immunoassays for Routine Use in a Diagnostic Laboratory. *Br J Biomed Sci* **2021**, *78*, 141–146, doi:10.1080/09674845.2020.1864108.

86. MacMullan, M.A.; Ibrayeva, A.; Trettner, K.; Deming, L.; Das, S.; Tran, F.; Moreno, J.R.; Casian, J.G.; Chellamuthu, P.; Kraft, J.; et al. ELISA Detection of SARS-CoV-2 Antibodies in Saliva. *Sci Rep* **2020**, *10*, 20818, doi:10.1038/s41598-020-77555-4.

87. Xiang, J.; Chen, Z.; Zhou, J.; Tian, D.; Ran, X.; Zhang, Z.; Shi, S.; Xiao, D.; Zhou, Y. Comparative Analysis of the Main Haematological Indexes and RNA Detection for the Diagnosis of SARS-CoV-2 Infection. *BMC Infect Dis* **2020**, *20*, 779, doi:10.1186/s12879-020-05489-3.

88. Rychert, J.; Couturier, M.R.; Elgort, M.; Lozier, B.K.; La'ulu, S.; Genzen, J.R.; Straseski, J.A.; Delgado, J.C.; Slev, P.R. Evaluation of 3 SARS-CoV-2 IgG Antibody Assays and Correlation with Neutralizing Antibodies. *J Appl Lab Med* **2021**, *6*, 614–624, doi:10.1093/jalm/jfaa188.

89. Indenbaum, V.; Koren, R.; Katz-Likvornik, S.; Yitzchaki, M.; Halpern, O.; Regev-Yochay, G.; Cohen, C.; Biber, A.; Feferman, T.; Cohen Saban, N.; et al. Testing IgG Antibodies against the RBD of SARS-CoV-2 Is Sufficient and Necessary for COVID-19 Diagnosis. *PLoS One* **2020**, *15*, e0241164, doi:10.1371/journal.pone.0241164.

90. Velay, A.; Gallais, F.; Benotmane, I.; Wendling, M.J.; Danion, F.; Collange, O.; De Sèze, J.; Schmidt-Mutter, C.; Schneider, F.; Bilbault, P.; et al. Evaluation of the Performance of SARS-CoV-2 Serological Tools and Their Positioning in COVID-19 Diagnostic Strategies. *Diagn Microbiol Infect Dis* **2020**, *98*, 115181, doi:10.1016/j.diagmicrobio.2020.115181.

91. Nandakumar, V.; Profaizer, T.; Lozier, B.K.; Elgort, M.G.; Larragoite, E.T.; Williams, E.S.C.P.; Solis-Leal, A.; Lopez, J.B.; Berges, B.K.; Planelles, V.; et al. Evaluation of a Surrogate Enzyme-Linked Immunosorbent Assay-Based Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) CPass Neutralization Antibody Detection Assay and Correlation With Immunoglobulin G

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Commercial Serology Assays. *Arch Pathol Lab Med* **2021**, *145*, 1212–1220, doi:10.5858/arpa.2021-0213-SA.

92. Perera, R.A.P.M.; Ko, R.; Tsang, O.T.Y.; Hui, D.S.C.; Kwan, M.Y.M.; Brackman, C.J.; To, E.M.W.; Yen, H.-L.; Leung, K.; Cheng, S.M.S.; et al. Evaluation of a SARS-CoV-2 Surrogate Virus Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera. *J Clin Microbiol* **2021**, *59*, e02504-20, doi:10.1128/JCM.02504-20.

93. Putcharoen, O.; Wacharapluesadee, S.; Chia, W.N.; Paitoonpong, L.; Tan, C.W.; Suwanpimolkul, G.; Jantarabenjakul, W.; Ruchisrisarod, C.; Wanthong, P.; Sophonphan, J.; et al. Early Detection of Neutralizing Antibodies against SARS-CoV-2 in COVID-19 Patients in Thailand. *PLoS One* **2021**, *16*, e0246864, doi:10.1371/journal.pone.0246864.

94. Irsara, C.; Egger, A.E.; Prokop, W.; Nairz, M.; Loacker, L.; Sahanic, S.; Pizzini, A.; Sonnweber, T.; Holzer, B.; Mayer, W.; et al. Clinical Validation of the Siemens Quantitative SARS-CoV-2 Spike IgG Assay (SCOVG) Reveals Improved Sensitivity and a Good Correlation with Virus Neutralization Titers. *Clin Chem Lab Med* **2021**, *59*, 1453–1462, doi:10.1515/cclm-2021-0214.

95. Thompson, C.P.; Grayson, N.E.; Paton, R.S.; Bolton, J.S.; Lourenço, J.; Penman, B.S.; Lee, L.N.; Odon, V.; Mongkolsapaya, J.; Chinnakannan, S.; et al. Detection of Neutralising Antibodies to SARS-CoV-2 to Determine Population Exposure in Scottish Blood Donors between March and May 2020. *Euro Surveill* **2020**, *25*, 2000685, doi:10.2807/1560-7917.ES.2020.25.42.2000685.

96. Zhu, X.; Wang, X.; Han, L.; Chen, T.; Wang, L.; Li, H.; Li, S.; He, L.; Fu, X.; Chen, S.; et al. Multiplex Reverse Transcription Loop-Mediated Isothermal Amplification Combined with Nanoparticle-Based Lateral Flow Biosensor for the Diagnosis of COVID-19. *Biosens Bioelectron* **2020**, *166*, 112437, doi:10.1016/j.bios.2020.112437.

97. Büyüksünetçi, Y.T.; Çitil, B.E.; Tapan, U.; Anık, Ü. Development and Application of a SARS-CoV-2 Colorimetric Biosensor Based on the Peroxidase-Mimic Activity of γ-Fe2O3 Nanoparticles. *Mikrochim Acta* **2021**, *188*, 335, doi:10.1007/s00604-021-04989-6.

98. Mavrikou, S.; Tsekouras, V.; Hatziagapiou, K.; Paradeisi, F.; Bakakos, P.; Michos, A.; Koutsoukou, A.; Konstantellou, E.; Lambrou, G.I.; Koniari, E.; et al. Clinical Application of the Novel Cell-Based Biosensor for the Ultra-Rapid Detection of the SARS-CoV-2 S1 Spike Protein Antigen: A Practical Approach. *Biosensors (Basel)* **2021**, *11*, 224, doi:10.3390/bios11070224.

99. Liv, L.; Çoban, G.; Nakiboğlu, N.; Kocagöz, T. A Rapid, Ultrasensitive Voltammetric Biosensor for Determining SARS-CoV-2 Spike Protein in Real Samples. *Biosens Bioelectron* **2021**, *192*, 113497, doi:10.1016/j.bios.2021.113497.

100. Apostolou, T.; Kyritsi, M.; Vontas, A.; Loizou, K.; Hadjilouka, A.; Speletas, M.; Mouchtouri, V.; Hadjichristodoulou, C. Development and Performance Characteristics Evaluation of a New Bioelectric Recognition Assay (BERA) Method for Rapid Sars-CoV-2 Detection in Clinical Samples. *J Virol Methods* **2021**, *293*, 114166, doi:10.1016/j.jviromet.2021.114166.

101. Zhu, X.; Wang, X.; Li, S.; Luo, W.; Zhang, X.; Wang, C.; Chen, Q.; Yu, S.; Tai, J.; Wang, Y. Rapid, Ultrasensitive, and Highly Specific Diagnosis of COVID-19 by CRISPR-Based Detection. *ACS Sens* **2021**, *6*, 881–888, doi:10.1021/acssensors.0c01984.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

102. Chaibun, T.; Puenpa, J.; Ngamdee, T.; Boonapatcharoen, N.; Athamanolap, P.; O'Mullane, A.P.; Vongpunsawad, S.; Poovorawan, Y.; Lee, S.Y.; Lertanantawong, B. Rapid Electrochemical Detection of Coronavirus SARS-CoV-2. *Nat Commun* **2021**, *12*, 802, doi:10.1038/s41467-021-21121-7.

103. Soleimani, R.; Khourssaji, M.; Gruson, D.; Rodriguez-Villalobos, H.; Berghmans, M.; Belkhir, L.; Yombi, J.-C.; Kabamba-Mukadi, B. Clinical Usefulness of Fully Automated Chemiluminescent Immunoassay for Quantitative Antibody Measurements in COVID-19 Patients. *J Med Virol* **2021**, *93*, 1465–1477, doi:10.1002/jmv.26430.

104. Lin, D.; Liu, L.; Zhang, M.; Hu, Y.; Yang, Q.; Guo, J.; Dai, Y.; Xu, Y.; Cai, Y.; Chen, X.; et al. Evaluations of the Serological Test in the Diagnosis of 2019 Novel Coronavirus (SARS-CoV-2) Infections during the COVID-19 Outbreak. *Eur J Clin Microbiol Infect Dis* **2020**, *39*, 2271–2277, doi:10.1007/s10096-020-03978-6.

105. Jung, K.; Shin, S.; Nam, M.; Hong, Y.J.; Roh, E.Y.; Park, K.U.; Song, E.Y. Performance Evaluation of Three Automated Quantitative Immunoassays and Their Correlation with a Surrogate Virus Neutralization Test in Coronavirus Disease 19 Patients and Pre-Pandemic Controls. *J Clin Lab Anal* **2021**, *35*, e23921, doi:10.1002/jcla.23921.

106. Sekirov, I.; Barakauskas, V.E.; Simons, J.; Cook, D.; Bates, B.; Burns, L.; Masud, S.; Charles, M.; McLennan, M.; Mak, A.; et al. SARS-CoV-2 Serology: Validation of High-Throughput Chemiluminescent Immunoassay (CLIA) Platforms and a Field Study in British Columbia. *J Clin Virol* **2021**, *142*, 104914, doi:10.1016/j.jcv.2021.104914.

107. Zonneveld, R.; Jurriaans, S.; van Gool, T.; Hofstra, J.J.; Hekker, T.A.M.; Defoer, P.; Broekhuizen-van Haaften, P.E.; Wentink-Bonnema, E.M.; Boonkamp, L.; Teunissen, C.E.; et al. Head-to-Head Validation of Six Immunoassays for SARS-CoV-2 in Hospitalized Patients. *J Clin Virol* **2021**, *139*, 104821, doi:10.1016/j.jcv.2021.104821.

108. Pérez-García, F.; Pérez-Tanoira, R.; Iglesias, M.E.; Romanyk, J.; Arroyo, T.; Gómez-Herruz, P.; González, R.; Lapeña García, S.; Cuadros-González, J. Comparative Evaluation of Six Immunoassays for the Detection of Antibodies against SARS-CoV-2. *J Virol Methods* **2021**, *289*, 114047, doi:10.1016/j.jviromet.2020.114047.

109. Jones, H.E.; Mulchandani, R.; Taylor-Phillips, S.; Ades, A.E.; Shute, J.; Perry, K.R.; Chandra, N.L.; Brooks, T.; Charlett, A.; Hickman, M.; et al. Accuracy of Four Lateral Flow Immunoassays for Anti SARS-CoV-2 Antibodies: A Head-to-Head Comparative Study. *EBioMedicine* **2021**, *68*, 103414, doi:10.1016/j.ebiom.2021.103414.

110. Robertson, L.J.; Moore, J.S.; Blighe, K.; Ng, K.Y.; Quinn, N.; Jennings, F.; Warnock, G.; Sharpe, P.; Clarke, M.; Maguire, K.; et al. Evaluation of the IgG Antibody Response to SARS CoV-2 Infection and Performance of a Lateral Flow Immunoassay: Cross-Sectional and Longitudinal Analysis over 11 Months. *BMJ Open* **2021**, *11*, e048142, doi:10.1136/bmjopen-2020-048142.

111. Kaku, N.; Nishimura, F.; Shigeishi, Y.; Tachiki, R.; Sakai, H.; Sasaki, D.; Ota, K.; Sakamoto, K.; Kosai, K.; Hasegawa, H.; et al. Performance of Anti-SARS-CoV-2 Antibody Testing in Asymptomatic or

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Mild COVID-19 Patients: A Retrospective Study in Outbreak on a Cruise Ship. *PLoS One* **2021**, *16*, e0257452, doi:10.1371/journal.pone.0257452.

112. Daoud, Z.; McLeod, J.; Stockman, D.L. Higher Sensitivity Provided by the Combination of Two Lateral Flow Immunoassay Tests for the Detection of COVID-19 Immunoglobulins. *Front Cell Infect Microbiol* **2020**, *10*, 479, doi:10.3389/fcimb.2020.00479.

113. McAulay, K.; Bryan, A.; Greninger, A.L.; Grill, F.; Lake, D.; Kaleta, E.J.; Grys, T.E. Retrospective Clinical Evaluation of 4 Lateral Flow Assays for the Detection of SARS-CoV-2 IgG. *Diagn Microbiol Infect Dis* **2020**, *98*, 115161, doi:10.1016/j.diagmicrobio.2020.115161.

114. Mulchandani, R.; Jones, H.E.; Taylor-Phillips, S.; Shute, J.; Perry, K.; Jamarani, S.; Brooks, T.; Charlett, A.; Hickman, M.; Oliver, I.; et al. Accuracy of UK Rapid Test Consortium (UK-RTC) "AbC-19 Rapid Test" for Detection of Previous SARS-CoV-2 Infection in Key Workers: Test Accuracy Study. *BMJ* **2020**, *371*, m4262, doi:10.1136/bmj.m4262.

115. Conte, D.D.; Carvalho, J.M.A.; de Souza Luna, L.K.; Faíco-Filho, K.S.; Perosa, A.H.; Bellei, N. Comparative Analysis of Three Point-of-Care Lateral Flow Immunoassays for Detection of Anti-SARS-CoV-2 Antibodies: Data from 100 Healthcare Workers in Brazil. *Braz J Microbiol* **2021**, *52*, 1161–1165, doi:10.1007/s42770-021-00498-z.

116. Chen, Z.; Zhang, Z.; Zhai, X.; Li, Y.; Lin, L.; Zhao, H.; Bian, L.; Li, P.; Yu, L.; Wu, Y.; et al. Rapid and Sensitive Detection of Anti-SARS-CoV-2 IgG, Using Lanthanide-Doped Nanoparticles-Based Lateral Flow Immunoassay. *Anal Chem* **2020**, *92*, 7226–7231, doi:10.1021/acs.analchem.0c00784.

117. Wang, C.; Shi, D.; Wan, N.; Yang, X.; Liu, H.; Gao, H.; Zhang, M.; Bai, Z.; Li, D.; Dai, E.; et al. Development of Spike Protein-Based Fluorescence Lateral Flow Assay for the Simultaneous Detection of SARS-CoV-2 Specific IgM and IgG. *Analyst* **2021**, *146*, 3908–3917, doi:10.1039/d1an00304f.

118. Wu, J.-L.; Tseng, W.-P.; Lin, C.-H.; Lee, T.-F.; Chung, M.-Y.; Huang, C.-H.; Chen, S.-Y.; Hsueh, P.-R.; Chen, S.-C. Four Point-of-Care Lateral Flow Immunoassays for Diagnosis of COVID-19 and for Assessing Dynamics of Antibody Responses to SARS-CoV-2. *J Infect* **2020**, *81*, 435–442, doi:10.1016/j.jinf.2020.06.023.

119. Cerutti, F.; Burdino, E.; Milia, M.G.; Allice, T.; Gregori, G.; Bruzzone, B.; Ghisetti, V. Urgent Need of Rapid Tests for SARS CoV-2 Antigen Detection: Evaluation of the SD-Biosensor Antigen Test for SARS-CoV-2. *J Clin Virol* **2020**, *132*, 104654, doi:10.1016/j.jcv.2020.104654.

120. Albert, E.; Torres, I.; Bueno, F.; Huntley, D.; Molla, E.; Fernández-Fuentes, M.Á.; Martínez, M.; Poujois, S.; Forqué, L.; Valdivia, A.; et al. Field Evaluation of a Rapid Antigen Test (Panbio™ COVID-19 Ag Rapid Test Device) for COVID-19 Diagnosis in Primary Healthcare Centres. *Clin Microbiol Infect* **2021**, *27*, 472.e7-472.e10, doi:10.1016/j.cmi.2020.11.004.

121. Pérez-García, F.; Romanyk, J.; Moya Gutiérrez, H.; Labrador Ballestero, A.; Pérez Ranz, I.; González Arroyo, J.; González Ventosa, V.; Pérez-Tanoira, R.; Domingo Cruz, C.; Cuadros-González, J. Comparative Evaluation of Panbio and SD Biosensor Antigen Rapid Diagnostic Tests for COVID-19 Diagnosis. *J Med Virol* **2021**, *93*, 5650–5654, doi:10.1002/jmv.27089.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

122. Eleftheriou, I.; Dasoula, F.; Dimopoulou, D.; Lebessi, E.; Serafi, E.; Spyridis, N.; Tsolia, M. Real-Life Evaluation of a COVID-19 Rapid Antigen Detection Test in Hospitalized Children. *J Med Virol* **2021**, *93*, 6040–6044, doi:10.1002/jmv.27149.

123. Igloi, Z.; Velzing, J.; van Beek, J.; van de Vijver, D.; Aron, G.; Ensing, R.; Benschop, K.; Han, W.; Boelsums, T.; Koopmans, M.; et al. Clinical Evaluation of Roche SD Biosensor Rapid Antigen Test for SARS-CoV-2 in Municipal Health Service Testing Site, the Netherlands. *Emerg Infect Dis* **2021**, *27*, 1323–1329, doi:10.3201/eid2705.204688.

124. Kurihara, Y.; Kiyasu, Y.; Akashi, Y.; Takeuchi, Y.; Narahara, K.; Mori, S.; Takeshige, T.; Notake, S.; Ueda, A.; Nakamura, K.; et al. The Evaluation of a Novel Digital Immunochromatographic Assay with Silver Amplification to Detect SARS-CoV-2. *J Infect Chemother* **2021**, *27*, 1493–1497, doi:10.1016/j.jiac.2021.07.006.

125. Kim, D.; Lee, J.; Bal, J.; Seo, S.K.; Chong, C.-K.; Lee, J.H.; Park, H. Development and Clinical Evaluation of an Immunochromatography-Based Rapid Antigen Test (GenBody™ COVAG025) for COVID-19 Diagnosis. *Viruses* **2021**, *13*, 796, doi:10.3390/v13050796.

126. Abusrewil, Z.; Alhudiri, I.M.; Kaal, H.H.; El Meshri, S.E.; Ebrahim, F.O.; Dalyoum, T.; Efrefer, A.A.; Ibrahim, K.; Elfghi, M.B.; Abusrewil, S.; et al. Time Scale Performance of Rapid Antigen Testing for SARS-CoV-2: Evaluation of 10 Rapid Antigen Assays. *J Med Virol* **2021**, *93*, 6512–6518, doi:10.1002/jmv.27186.

127. Torres, I.; Poujois, S.; Albert, E.; Colomina, J.; Navarro, D. Evaluation of a Rapid Antigen Test (Panbio™ COVID-19 Ag Rapid Test Device) for SARS-CoV-2 Detection in Asymptomatic Close Contacts of COVID-19 Patients. *Clin Microbiol Infect* **2021**, *27*, 636.e1-636.e4, doi:10.1016/j.cmi.2020.12.022.

128. Gupta, A.; Khurana, S.; Das, R.; Srigyan, D.; Singh, A.; Mittal, A.; Singh, P.; Soneja, M.; Kumar, A.; Singh, A.K.; et al. Rapid Chromatographic Immunoassay-Based Evaluation of COVID-19: A Cross-Sectional, Diagnostic Test Accuracy Study & Its Implications for COVID-19 Management in India. *Indian J Med Res* **2021**, *153*, 126–131, doi:10.4103/ijmr.IJMR_3305_20.

129. Oh, S.M.; Jeong, H.; Chang, E.; Choe, P.G.; Kang, C.K.; Park, W.B.; Kim, T.S.; Kwon, W.Y.; Oh, M.D.; Kim, N.J. Clinical Application of the Standard Q COVID-19 Ag Test for the Detection of SARS-CoV-2 Infection. *J Korean Med Sci* **2021**, *36*, e101, doi:10.3346/jkms.2021.36.e101.

130. Ferté, T.; Ramel, V.; Cazanave, C.; Lafon, M.-E.; Bébéar, C.; Malvy, D.; Georges-Walryck, A.; Dehail, P. Accuracy of COVID-19 Rapid Antigenic Tests Compared to RT-PCR in a Student Population: The StudyCov Study. *J Clin Virol* **2021**, *141*, 104878, doi:10.1016/j.jcv.2021.104878.

131. Kyritsi, M.; Vontas, A.; Voulgaridi, I.; Matziri, A.; Komnos, A.; Babalis, D.; Papadogoulas, A.; Oikonomou, A.; Mouchtouri, V.A.; Speletas, M.; et al. Rapid Test Ag 2019-NCoV (PROGNOSIS, BIOTECH, Larissa, Greece); Performance Evaluation in Hospital Setting with Real Time RT-PCR. *Int J Environ Res Public Health* **2021**, *18*, 9151, doi:10.3390/ijerph18179151.

132. Jakobsen, K.K.; Jensen, J.S.; Todsen, T.; Tolsgaard, M.G.; Kirkby, N.; Lippert, F.; Vangsted, A.-M.; Martel, C.J.-M.; Klokker, M.; von Buchwald, C. Accuracy and Cost Description of Rapid Antigen

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Test Compared with Reverse Transcriptase-Polymerase Chain Reaction for SARS-CoV-2 Detection. *Dan Med J* **2021**, *68*, A03210217.

133. Charpentier, C.; Ichou, H.; Damond, F.; Bouvet, E.; Chaix, M.-L.; Ferré, V.; Delaugerre, C.; Mahjoub, N.; Larrouy, L.; Le Hingrat, Q.; et al. Performance Evaluation of Two SARS-CoV-2 IgG/IgM Rapid Tests (Covid-Presto and NG-Test) and One IgG Automated Immunoassay (Abbott). *Journal of clinical virology* **2020**, *132*, 104618, doi:10.1016/j.jcv.2020.104618.

134. Orsi, A.; Pennati, B.M.; Bruzzone, B.; Ricucci, V.; Ferone, D.; Barbera, P.; Arboscello, E.; Dentone, C.; Icardi, G. On-Field Evaluation of a Ultra-Rapid Fluorescence Immunoassay as a Frontline Test for SARS-CoV-2 Diagnostic. *J Virol Methods* **2021**, *295*, 114201, doi:10.1016/j.jviromet.2021.114201.

135. Baccani, I.; Morecchiato, F.; Chilleri, C.; Cervini, C.; Gori, E.; Matarrese, D.; Bassetti, A.; Bonizzoli, M.; Mencarini, J.; Antonelli, A.; et al. Evaluation of Three Immunoassays for the Rapid Detection of SARS-CoV-2 Antigens. *Diagn Microbiol Infect Dis* **2021**, *101*, 115434, doi:10.1016/j.diagmicrobio.2021.115434.

136. MacMullan, M.A.; Chellamuthu, P.; Mades, A.; Das, S.; Turner, F.; Slepnev, V.I.; Ibrayeva, A. Detection of SARS-CoV-2 Antibodies in Oral Fluid Obtained Using a Rapid Collection Device. *J Clin Microbiol* **2021**, *59*, e02510-20, doi:10.1128/JCM.02510-20.

137. Mullins, K.E.; Merrill, V.; Ward, M.; King, B.; Rock, P.; Caswell, M.; Ahlman, M.; Harris, A.D.; Christenson, R. Validation of COVID-19 Serologic Tests and Large Scale Screening of Asymptomatic Healthcare Workers. *Clin Biochem* **2021**, *90*, 23–27, doi:10.1016/j.clinbiochem.2021.01.004.

138. Hirotsu, Y.; Maejima, M.; Shibusawa, M.; Nagakubo, Y.; Hosaka, K.; Amemiya, K.; Sueki, H.; Hayakawa, M.; Mochizuki, H.; Tsutsui, T.; et al. Comparison of Automated SARS-CoV-2 Antigen Test for COVID-19 Infection with Quantitative RT-PCR Using 313 Nasopharyngeal Swabs, Including from Seven Serially Followed Patients. *Int J Infect Dis* **2020**, *99*, 397–402, doi:10.1016/j.ijid.2020.08.029.

139. Asai, N.; Sakanashi, D.; Ohashi, W.; Nakamura, A.; Kawamoto, Y.; Miyazaki, N.; Ohno, T.; Yamada, A.; Chida, S.; Shibata, Y.; et al. Efficacy and Validity of Automated Quantitative Chemiluminescent Enzyme Immunoassay for SARS-CoV-2 Antigen Test from Saliva Specimen in the Diagnosis of COVID-19. *J Infect Chemother* **2021**, *27*, 1039–1042, doi:10.1016/j.jiac.2021.03.021.

140. Paul, D.; Gupta, A.; Rooge, S.; Gupta, E. Performance Evaluation of Automated Chemiluminescence Immunoassay Based Antigen Detection - Moving towards More Reliable Ways to Predict SARS-CoV-2 Infection. *J Virol Methods* **2021**, *298*, 114299, doi:10.1016/j.jviromet.2021.114299.

141. Candia-Puma, M.A.; Machaca-Luque, L.Y.; Roque-Pumahuanca, B.M.; Galdino, A.S.; Giunchetti, R.C.; Coelho, E.A.F.; Chávez-Fumagalli, M.A. Accuracy of Diagnostic Tests for the Detection of Chagas Disease: A Systematic Review and Meta-Analysis. *Diagnostics* **2022**, *12*, 2752, doi:10.3390/diagnostics12112752.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

142. Chávez-Fumagalli, M.A.; Shrivastava, P.; Aguilar-Pineda, J.A.; Nieto-Montesinos, R.; Davila del Carpio, G.; Peralta-Mestas, A.; Caracela-Zeballos, C.; Valdez-Lazo, G.; Fernandez-Macedo, V.; Pino-Figueroa, A.; et al. Diagnosis of Alzheimer's Disease in Developed and Developing Countries: Systematic Review and Meta-Analysis of Diagnostic Test Accuracy. *J Alzheimers Dis Rep* **2021**, *5*, 15–30, doi:10.3233/ADR-200263.

143. Sachs, J.D.; Karim, S.S.A.; Aknin, L.; Allen, J.; Brosbøl, K.; Colombo, F.; Barron, G.C.; Espinosa, M.F.; Gaspar, V.; Gaviria, A.; et al. The Lancet Commission on Lessons for the Future from the COVID-19 Pandemic. *The Lancet* **2022**, *400*, 1224–1280, doi:10.1016/S0140-6736(22)01585-9.

144. Singh, S.; Mcnab, C.; Olson, R.M.; Bristol, N.; Nolan, C.; Bergstrøm, E.; Bartos, M.; Mabuchi, S.; Panjabi, R.; Karan, A.; et al. How an Outbreak Became a Pandemic: A Chronological Analysis of Crucial Junctures and International Obligations in the Early Months of the COVID-19 Pandemic. *The Lancet* **2021**, *398*, 2109–2124, doi:10.1016/S0140-6736(21)01897-3.

145. Zhang, M.; Wang, S.; Hu, T.; Fu, X.; Wang, X.; Hu, Y.; Halloran, B.; Li, Z.; Cui, Y.; Liu, H.; et al. Human Mobility and COVID-19 Transmission: A Systematic Review and Future Directions. *Ann GIS* **2022**, 1–14, doi:10.1080/19475683.2022.2041725.

146. Gao, W.; Lv, J.; Pang, Y.; Li, L.-M. Role of Asymptomatic and Pre-Symptomatic Infections in Covid-19 Pandemic. *BMJ* **2021**, *375*, n2342, doi:10.1136/bmj.n2342.

147. Ravindra, K.; Malik, V.S.; Padhi, B.K.; Goel, S.; Gupta, M. Asymptomatic Infection and Transmission of COVID-19 among Clusters: Systematic Review and Meta-Analysis. *Public Health* **2022**, *203*, 100–109, doi:10.1016/j.puhe.2021.12.003.

148. Gao, Z.; Xu, Y.; Sun, C.; Wang, X.; Guo, Y.; Qiu, S.; Ma, K. A Systematic Review of Asymptomatic Infections with COVID-19. *Journal of Microbiology, Immunology and Infection* **2021**, *54*, 12–16, doi:10.1016/j.jmii.2020.05.001.

149. Laccourreye, O.; Cohen, R.; Couloigner, V. Keys for Analysis of Diagnostic and Serologic Tests for CoV-2. *Eur Ann Otorhinolaryngol Head Neck Dis* **2020**, *137*, 323–324, doi:10.1016/j.anorl.2020.05.013.

150. Martín, J.; Tena, N.; Asuero, A.G. Current State of Diagnostic, Screening and Surveillance Testing Methods for COVID-19 from an Analytical Chemistry Point of View. *Microchemical Journal* **2021**, *167*, 106305, doi:10.1016/j.microc.2021.106305.

151. Habibzadeh, P.; Mofatteh, M.; Silawi, M.; Ghavami, S.; Faghihi, M.A. Molecular Diagnostic Assays for COVID-19: An Overview. *Crit Rev Clin Lab Sci* **2021**, *58*, 385–398, doi:10.1080/10408363.2021.1884640.

152. Chau, C.H.; Strope, J.D.; Figg, W.D. COVID-19 Clinical Diagnostics and Testing Technology. *Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy* **2020**, *40*, 857–868, doi:10.1002/phar.2439.

153. Kwok, H.F. The Significance of Advanced COVID-19 Diagnostic Testing in Pandemic Control Measures. *Int J Biol Sci* **2022**, *18*, 4610, doi:10.7150/ijbs.72837.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

154. Carpenter, C.R.; Mudd, P.A.; West, C.P.; Wilber, E.; Wilber, S.T. Diagnosing COVID-19 in the Emergency Department: A Scoping Review of Clinical Examinations, Laboratory Tests, Imaging Accuracy, and Biases. *Academic Emergency Medicine* **2020**, *27*, 653–670, doi:10.1111/acem.14048.

155. Guglielmi, G. The Explosion of New Coronavirus Tests That Could Help to End the Pandemic. *Nature* **2020**, *583*, 506–509, doi:10.1038/d41586-020-02140-8.

156. Vandenberg, O.; Martiny, D.; Rochas, O.; van Belkum, A.; Kozlakidis, Z. Considerations for Diagnostic COVID-19 Tests. *Nat Rev Microbiol* **2021**, *19*, 171–183, doi:10.1038/s41579-020-00461-z.

157. Jeong, S.; González-Grandío, E.; Navarro, N.; Pinals, R.L.; Ledesma, F.; Yang, D.; Landry, M.P. Extraction of Viral Nucleic Acids with Carbon Nanotubes Increases SARS-CoV-2 Quantitative Reverse Transcription Polymerase Chain Reaction Detection Sensitivity. *ACS Nano* **2021**, *15*, 10309–10317, doi:10.1021/acsnano.1c02494.

158. El Jaddaoui, I.; Allali, M.; Raoui, S.; Sehli, S.; Habib, N.; Chaouni, B.; Al Idrissi, N.; Benslima, N.; Maher, W.; Benrahma, H.; et al. A Review on Current Diagnostic Techniques for COVID-19. *Expert Rev Mol Diagn* **2021**, *21*, 141–160, doi:10.1080/14737159.2021.1886927.

159. Teymouri, M.; Mollazadeh, S.; Mortazavi, H.; Naderi Ghale-noie, Z.; Keyvani, V.; Aghababaei, F.; Hamblin, M.R.; Abbaszadeh-Goudarzi, G.; Pourghadamyari, H.; Hashemian, S.M.R.; et al. Recent Advances and Challenges of RT-PCR Tests for the Diagnosis of COVID-19. *Pathol Res Pract* **2021**, *221*, 153443, doi:10.1016/j.prp.2021.153443.

160. Rahimi, H.; Salehiabar, M.; Barsbay, M.; Ghaffarlou, M.; Kavetskyy, T.; Sharafi, A.; Davaran, S.; Chauhan, S.C.; Danafar, H.; Kaboli, S.; et al. CRISPR Systems for COVID-19 Diagnosis. *ACS Sens* **2021**, *6*, 1430–1445, doi:10.1021/acssensors.0c02312.

161. Tahamtan, A.; Ardebili, A. Real-Time RT-PCR in COVID-19 Detection: Issues Affecting the Results. *Expert Rev Mol Diagn* **2020**, *20*, 453–454, doi:10.1080/14737159.2020.1757437.

162. Jiang, C.; Li, X.; Ge, C.; Ding, Y.; Zhang, T.; Cao, S.; Meng, L.; Lu, S. Molecular Detection of SARS-CoV-2 Being Challenged by Virus Variation and Asymptomatic Infection. *J Pharm Anal* **2021**, *11*, 257–264, doi:10.1016/j.jpha.2021.03.006.

163. Thompson, D.; Lei, Y. Mini Review: Recent Progress in RT-LAMP Enabled COVID-19 Detection. *Sensors and Actuators Reports* **2020**, *2*, 100017, doi:10.1016/j.snr.2020.100017.

164. Abbasi, J. The Promise and Peril of Antibody Testing for COVID-19. *JAMA* **2020**, *323*, 1881, doi:10.1001/jama.2020.6170.

165. Afzal, A. Molecular Diagnostic Technologies for COVID-19: Limitations and Challenges. *J Adv Res* **2020**, *26*, 149–159, doi:10.1016/j.jare.2020.08.002.

166. Mohit, E.; Rostami, Z.; Vahidi, H. A Comparative Review of Immunoassays for COVID-19 Detection. *Expert Rev Clin Immunol* **2021**, *17*, 573–599, doi:10.1080/1744666X.2021.1908886.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

167. Ong, D.S.Y.; Fragkou, P.C.; Schweitzer, V.A.; Chemaly, R.F.; Moschopoulos, C.D.; Skevaki, C. How to Interpret and Use COVID-19 Serology and Immunology Tests. *Clinical Microbiology and Infection* **2021**, *27*, 981–986, doi:10.1016/j.cmi.2021.05.001.

168. Zhang, J.J.Y.; Lee, K.S.; Ong, C.W.; Chan, M.Y.; Ang, L.W.; Leo, Y.S.; Chen, M.I.; Lye, D.C.B.; Young, B.E. Diagnostic Performance of COVID-19 Serological Assays during Early Infection: A Systematic Review and Meta-analysis of 11 516 Samples. *Influenza Other Respir Viruses* **2021**, *15*, 529–538, doi:10.1111/irv.12841.

169. Yong, S.E.F.; Anderson, D.E.; Wei, W.E.; Pang, J.; Chia, W.N.; Tan, C.W.; Teoh, Y.L.; Rajendram, P.; Toh, M.P.H.S.; Poh, C.; et al. Connecting Clusters of COVID-19: An Epidemiological and Serological Investigation. *Lancet Infect Dis* **2020**, *20*, 809–815, doi:10.1016/S1473-3099(20)30273-5.

170. Neagu, M.; Constantin, C.; Surcel, M. Testing Antigens, Antibodies, and Immune Cells in COVID-19 as a Public Health Topic—Experience and Outlines. *Int J Environ Res Public Health* **2021**, *18*, 13173, doi:10.3390/ijerph182413173.

171. Combadière, B. Immunité Adaptative Contre Le Virus SARS-CoV-2. *médecine/sciences* **2020**, *36*, 908–913, doi:10.1051/medsci/2020168.

172. Ma, H.; Zeng, W.; He, H.; Zhao, D.; Jiang, D.; Zhou, P.; Cheng, L.; Li, Y.; Ma, X.; Jin, T. Serum IgA, IgM, and IgG Responses in COVID-19. *Cell Mol Immunol* **2020**, *17*, 773–775, doi:10.1038/s41423-020-0474-z.

173. Gong, F.; Wei, H.; Li, Q.; Liu, L.; Li, B. Evaluation and Comparison of Serological Methods for COVID-19 Diagnosis. *Front Mol Biosci* **2021**, *8*, 1–12, doi:10.3389/fmolb.2021.682405.

174. Batra, R.; Olivieri, L.G.; Rubin, D.; Vallari, A.; Pearce, S.; Olivo, A.; Prostko, J.; Nebbia, G.; Douthwaite, S.; Rodgers, M.; et al. A Comparative Evaluation between the Abbott Panbio™ COVID-19 IgG/IgM Rapid Test Device and Abbott Architect™ SARS CoV-2 IgG Assay. *Journal of Clinical Virology* **2020**, *132*, 104645, doi:10.1016/j.jcv.2020.104645.

175. Malik, Y.A. Properties of Coronavirus and SARS-CoV-2. *Malays J Pathol* **2020**, *42*, 3–11.

176. Zeng, W.; Liu, G.; Ma, H.; Zhao, D.; Yang, Y.; Liu, M.; Mohammed, A.; Zhao, C.; Yang, Y.; Xie, J.; et al. Biochemical Characterization of SARS-CoV-2 Nucleocapsid Protein. *Biochem Biophys Res Commun* **2020**, *527*, 618–623, doi:10.1016/j.bbrc.2020.04.136.

177. Li, T.; Wang, L.; Wang, H.; Li, X.; Zhang, S.; Xu, Y.; Wei, W. Serum SARS-COV-2 Nucleocapsid Protein: A Sensitivity and Specificity Early Diagnostic Marker for SARS-COV-2 Infection. *Front Cell Infect Microbiol* **2020**, *10*, 1–8, doi:10.3389/fcimb.2020.00470.

178. Mohit, E.; Rostami, Z.; Vahidi, H. A Comparative Review of Immunoassays for COVID-19 Detection. *Expert Rev Clin Immunol* **2021**, *17*, 573–599, doi:10.1080/1744666X.2021.1908886.

179. Lu, Y.; Wang, J.; Li, Q.; Hu, H.; Lu, J.; Chen, Z. Advances in Neutralization Assays for SARS-CoV-2. *Scand J Immunol* **2021**, *94*, doi:10.1111/sji.13088.

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

180. Chen, X.; Pan, Z.; Yue, S.; Yu, F.; Zhang, J.; Yang, Y.; Li, R.; Liu, B.; Yang, X.; Gao, L.; et al. Disease Severity Dictates SARS-CoV-2-Specific Neutralizing Antibody Responses in COVID-19. *Signal Transduct Target Ther* **2020**, *5*, 180, doi:10.1038/s41392-020-00301-9.

181. Muruato, A.E.; Fontes-Garfias, C.R.; Ren, P.; Garcia-Blanco, M.A.; Menachery, V.D.; Xie, X.; Shi, P.-Y. A High-Throughput Neutralizing Antibody Assay for COVID-19 Diagnosis and Vaccine Evaluation. *Nat Commun* **2020**, *11*, 4059, doi:10.1038/s41467-020-17892-0.

182. John, G.; Sahajpal, N.S.; Mondal, A.K.; Ananth, S.; Williams, C.; Chaubey, A.; Rojiani, A.M.; Kolhe, R. Next-Generation Sequencing (NGS) in COVID-19: A Tool for SARS-CoV-2 Diagnosis, Monitoring New Strains and Phylodynamic Modeling in Molecular Epidemiology. *Curr Issues Mol Biol* **2021**, *43*, 845–867, doi:10.3390/cimb43020061.

183. Yoo, S.M.; Choi, J.H.; Lee, S.Y.; Yoo, N.C. Applications of DNA Microarray in Disease Diagnostics. *J Microbiol Biotechnol* **2009**, *19*, 635–646, doi:10.4014/jmb.0803.226.

184. Xu, M.; Wang, D.; Wang, H.; Zhang, X.; Liang, T.; Dai, J.; Li, M.; Zhang, J.; Zhang, K.; Xu, D.; et al. COVID-19 Diagnostic Testing: Technology Perspective. *Clin Transl Med* **2020**, *10*, 1–15, doi:10.1002/ctm2.158.

185. Irungbam, M.; Chitkara, A.; Singh, V.K.; Sonkar, S.C.; Dubey, A.; Bansal, A.; Shrivastava, R.; Goswami, B.; Manchanda, V.; Saxena, S.; et al. Evaluation of Performance of Detection of Immunoglobulin G and Immunoglobulin M Antibody Against Spike Protein of SARS-CoV-2 by a Rapid Kit in a Real-Life Hospital Setting. *Front Microbiol* **2022**, *13*, 802292, doi:10.3389/fmicb.2022.802292.

186. Pieri, M.; Ciotti, M.; Carlozzi, N.; Frassanito, M.L.; Meloni, A.; Cistera, A.; Turchetti, G.; Niscola, S.; Labate, G.; Calugi, G.; et al. SARS-CoV-2 Infection Serology Validation of Different Methods: Usefulness of IgA in the Early Phase of Infection. *Clinica Chimica Acta* **2020**, *511*, 28–32, doi:10.1016/j.cca.2020.09.033.

187. Gopalakrishnan, S.; Ganeshkumar, P. Systematic Reviews and Meta-Analysis: Understanding the Best Evidence in Primary Healthcare. *J Family Med Prim Care* **2013**, *2*, 9, doi:10.4103/2249-4863.109934.

188. Tatsioni, A. Challenges in Systematic Reviews of Diagnostic Technologies. *Ann Intern Med* **2005**, *142*, 1048, doi:10.7326/0003-4819-142-12_Part_2-200506211-00004.

189. de França, N.C.; Campêlo, G.L.; de França, J.M.S.; Vale, E.G.; Badagnan, T.F. A Decomposition Analysis for Socioeconomic Inequalities in Health Status Associated with the COVID-19 Diagnosis and Related Symptoms during Brazil's First Wave of Infections. *Economía* **2021**, *22*, 251–264, doi:10.1016/j.econ.2021.09.002.

Figure Legends

Figure 1. A systematic review and meta-analysis flow diagram of the study selection process.

Figure 2. Selected articles using the PubMed database for the different diagnostic techniques using MeSH terms. A) Network map built by VOSviewer based on the co-occurrence

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

of MeSH terms. B) Number of articles found with the search for each diagnostic test, considered from cluster analysis.

Figure 3. The geographical location of COVID-19 studies. A) The pie chart shows the type of diagnostic tests used in the COVID-19 studies for the meta-analysis. B) The bar graph shows the number of COVID-19 studies, included in the meta-analysis, carried out by different countries. C) Demographic representation of COVID-19 studies, included in the meta-analysis, worldwide (lower-blue to upper-red numbers)

Figure 4. Data analysis and paired forest plot of the sensitivity and specificity of the reverse transcription–polymerase chain reaction (RT-PCR) in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [44–58].

Figure 5. Data analysis and paired forest plot of the sensitivity and specificity of the reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [59–65].

Figure 6. Data analysis and paired forest plot of the sensitivity and specificity of the clustered regularly interspaced short palindromic repeats (CRISPR) in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [66–72].

Figure 7. Data analysis and paired forest plot of the sensitivity and specificity of the enzyme-linked immunosorbent assay (ELISA) for IgG in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [73–88].

Figure 8. Data analysis and paired forest plot of the sensitivity and specificity of the enzyme-linked immunosorbent assay (ELISA) for IgM in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [74,84,87,89,90].

Figure 9. Data analysis and paired forest plot of the sensitivity and specificity of the enzyme-linked immunosorbent assay (ELISA) for IgA in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [74,75,77,89,90].

Figure 10. Data analysis and paired forest plot of the sensitivity and specificity of the antiviral neutralization bioassay (ANB) in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [91–95].

Figure 11. Data analysis and paired forest plot of the sensitivity and specificity of the biosensors (BS) in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [96–102].

Figure 12. Data analysis and paired forest plot of the sensitivity and specificity of the chemiluminescence immunoassay (CLIA) for IgG in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [76,77,79,88,103–107].

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Figure 13. Data analysis and paired forest plot of the sensitivity and specificity of the chemiluminescence immunoassay (CLIA) for IgM in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [77,79,103,104,106].

Figure 14. Data analysis and paired forest plot of the sensitivity and specificity of the chemiluminescence immunoassay (CLIA) for IgM-IgG in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [77,85,103,106,108].

Figure 15. Data analysis and paired forest plot of the sensitivity and specificity of the lateral flow immunoassay (LFIA) for IgG in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [75,77,79,109–116].

Figure 16. Data analysis and paired forest plot of the sensitivity and specificity of the lateral flow immunoassay (LFIA) for IgM in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [75,77,79,111,112,115].

Figure 17. Data analysis and paired forest plot of the sensitivity and specificity of the lateral flow immunoassay (LFIA) for IgM-IgG in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [75,77,85,90,108,109,115,117,118].

Figure 18. Data analysis and paired forest plot of the sensitivity and specificity of the lateral flow immunoassay (LFIA) for N-protein in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [119–132].

Figure 19. Data analysis and paired forest plot of the sensitivity and specificity of the chemiluminescent microparticle immunoassay (CMIA) in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [81,88,105,107,133].

Figure 20. Data analysis and paired forest plot of the sensitivity and specificity of the fluorescence immunoassay (FIA) in the diagnosis of COVID-19. Sensitivity and specificity are reported as a mean (95% confidence limits). The forest plot represents the estimated sensitivity and specificity (black squares) and their 95% confidence limits (horizontal black line) [121,134,135].

Figure 21. Meta-analysis of diagnostic test accuracy analysis. Summary receiver operating curve (sROC) plot of false positive rate and sensitivity. Comparison between RT-PCR, RT-LAMP, CRISPR, ELISA IgG, ELISA IgM, ELISA IgA, ABN, BS, CLIA IgG, CLIA IgM, CLIA IgM-IgG, LFIA IgG, LFIA IgM, LFIA IgM-IgG, LFIA N protein, CMIA and FIA methods in the diagnosis of COVID-19.

Supplementary 1. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of reverse transcription–polymerase chain reaction (RT-PCR) in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [44–58].

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Supplementary 2. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of reverse transcriptase loop-mediated isothermal amplification (RT-LAMP) in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [59–65].

Supplementary 3. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of clustered regularly interspaced short palindromic repeats (CRISPR) in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [66–72].

Supplementary 4. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of enzyme-linked immunosorbent assay (ELISA) for IgG in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [73–88].

Supplementary 5. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of enzyme-linked immunosorbent assay (ELISA) for IgM in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [74,84,87,89,90].

Supplementary 6. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of enzyme-linked immunosorbent assay (ELISA) for IgA in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [74,75,77,89,90].

Supplementary 7. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of antiviral neutralization bioassay (ANB) in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [91–95].

Supplementary 8. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of biosensors (BS) in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [96–102].

Supplementary 9. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of chemiluminescence immunoassay (CLIA) for IgG in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [76,77,79,88,103–107].

Supplementary 10. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of chemiluminescence immunoassay (CLIA) for IgM in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [77,79,103,104,106].

Supplementary 11. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of chemiluminescence immunoassay (CLIA) for IgM-IgG in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [77,85,103,106,108].

Supplementary 12. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of lateral flow immunoassay (LFIA) for IgG in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [75,77,79,109–116].

Supplementary 13. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of lateral flow immunoassay (LFIA) for IgM in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [75,77,79,111,112,115].

Supplementary 14. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of lateral flow immunoassay (LFIA) for IgM-IgG in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [75,77,85,90,108,109,115,117,118].

Supplementary 15. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of lateral flow immunoassay (LFIA) for N-protein in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [119–132].

Supplementary 16. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of chemiluminescent microparticle immunoassay (CMIA) in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [81,88,105,107,133].

Supplementary 17. Study data and paired forest plot of the Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio of fluorescence immunoassay (FIA) in the diagnosis of COVID-19. Positive Likelihood ratio, Negative likelihood ratio, and Diagnostic Odds ratio are reported with a mean (95% confidence limits). The Forest plot depicts the estimated sensitivity and specificity (black squares) and its 95% confidence limits (horizontal black line) [121,134,135].

Table S1. PRISMA 2020 Checklist

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Study	Sensitivity (95% CI)	Specificity (95% CI)
Visseaux 2020 − Altona Diagnostics	0.97 (0.87 - 0.99)	0.96 (0.85 - 0.99)
Ghoshal 2021 − Molbio Diagnostics	0.69 (0.62 - 0.76)	0.91 (0.89 - 0.92)
Gadkar 2021 − Internal	0.99 (0.96 - 1.00)	1.00 (0.98 - 1.00)
Hernández 2021 − Quantumdx	0.99 (0.91 - 1.00)	0.95 (0.84 - 0.98)
Hernández 2021 − GeneFinder	0.93 (0.82 - 0.97)	0.99 (0.90 - 1.00)
Hernández 2021 − Seegene	0.87 (0.75 - 0.94)	0.99 (0.90 - 1.00)
Hernández 2021 − MiRXES	0.87 (0.75 - 0.94)	0.97 (0.87 - 0.99)
Hernández 2021 − Sansure Biotech	0.93 (0.82 - 0.97)	0.90 (0.78 - 0.96)
Hernández 2021 − InBios International	0.95 (0.85 - 0.98)	0.99 (0.90 - 1.00)
Hernández 2021 − JN Medsys	0.99 (0.91 - 1.00)	0.79 (0.66 - 0.89)
Hernández 2021 − Patients Choice Laboratories	0.95 (0.85 - 0.98)	0.92 (0.81 - 0.97)
Fitoussi 2021− Credo Diagnostics Biomedical	0.90 (0.84 - 0.94)	0.98 (0.94 - 1.00)
Castineiras 2021 − Internal	0.89 (0.81 - 0.94)	1.00 (0.98 - 1.00)
Zowawi 2021 − Biomeme	0.99 (0.94 - 1.00)	0.97 (0.92 - 0.99)
Altamimi 2021 − BGI	0.99 (0.93 - 1.00)	0.95 (0.82 - 0.99)
Altamimi 2021 − Altona Diagnostics	0.95 (0.86 - 0.98)	0.98 (0.87 - 1.00)
Altamimi 2021 − Genesig	0.95 (0.86 - 0.98)	0.98 (0.87 - 1.00)
Altamimi 2021 − GeneReach Biotechnology	0.99 (0.93 - 1.00)	0.98 (0.87 - 1.00)
Altamimi 2021 − OPTOLANE	0.98 (0.90 - 0.99)	0.95 (0.82 - 0.99)
Altamimi 2021 − Kogene Biotech	0.96 (0.88 - 0.99)	0.95 (0.82 - 0.99)
Altamimi 2021 − Sansure Biotech	0.99 (0.93 - 1.00)	0.95 (0.82 - 0.99)
Altamimi 2021 − Solgent	0.98 (0.90 - 0.99)	0.98 (0.87 - 1.00)
Altamimi 2021 − Thermo Fisher Scientific	0.95 (0.86 - 0.98)	0.98 (0.87 - 1.00)
Altamimi 2021 − TIB Molbiol	0.95 (0.86, - 0.98)	0.98 (0.87 - 1.00)
Altamimi 2021 − Quidel	0.66 (0.54 - 0.77)	0.98 (0.87 - 1.00)
Altamimi 2021 − KH Medical	0.99 (0.93 - 1.00)	0.98 (0.87 - 1.00)
Al Suwaidi 2021 − Seegene	0.86 (0.76 - 0.92)	0.98 (0.97 - 0.99)
Visseaux 2021 − Takara Bio USA (A)	0.55 (0.43 - 0.66)	0.87 (0.69 - 0.95)
Visseaux 2021 − Takara Bio USA (B)	0.69 (0.58 - 0.79)	0.98 (0.84 - 1.00)
Visseaux 2021 − Sansure Biotech	0.69 (0.58 - 0.79)	0.98 (0.84 - 1.00)
Bustin 2021− Internal	0.98 (0.83 - 1.00)	0.92 (0.52 - 0.99)
Rajh 2021 − Internal	0.95 (0.89 - 0.98)	0.99 (0.95 - 1.00)
Abdullah 2021 − MiRXES	0.37 (0.29 - 0.46)	0.91 (0.69 - 0.98)
Singh 2021 − Thermo Fisher Scientific	0.88 (0.79 - 0.93)	0.98 (0.86 - 1.00)
Singh 2021 − LabGenomics	0.93 (0.86 - 0.97)	0.98 (0.86 - 1.00)
Singh 2021 − Seegene	0.88 (0.79 - 0.93)	0.98 (0.86 - 1.00)
Singh 2021 − BGI	0.80 (0.71 - 0.87)	0.98 (0.86 - 1.00)
Singh 2021 − TRUPCR Europe	0.73 (0.63 - 0.81)	0.98 (0.86 - 1.00)
Chang 2021 − Internal	0.95 (0.82 - 0.99)	0.96 (0.89 - 0.99)



Study	Sensitivity (95%CI)	Specificity (95%CI)
Rödel 2020 − Amplex Diagnostics	0.75 [0.65, 0.82]	0.99 [0.90, 1.00]
Hu 2020 − Internal	0.88 [0.73, 0.95]	0.99 [0.97, 1.00]
Lee 2020 − Internal	0.87 [0.79, 0.92]	0.99 [0.91, 1.00]
Jiang 2020 − Internal	0.91 [0.79, 0.96]	0.99 [0.97, 1.00]
Dao 2020 − Internal	0.97 [0.91, 0.99]	1.00 [0.99, 1.00]
Lu 2021 − Internal	0.93 [0.80, 0.98]	0.88 [0.68, 0.96]
Schmidt 2021 − Internal (CA)	0.99 [0.89, 1.00]	0.94 [0.79, 0.99]
Schmidt 2021 − Internal (SA)	0.93 [0.80, 0.98]	0.99 [0.88, 1.00]



medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Study	Sensitivity (95%CI)	Specificity (95%CI)
Chen 2020 − Internal	0.94 [0.60, 0.99]	0.88 [0.40, 0.99]
Hou 2020 − Internal	0.99 [0.92, 1.00]	0.95 [0.66, 0.99]
Xiong 2020 − Internal	0.96 [0.84, 0.99]	0.98 [0.86, 1.00]
Li 2021 − Internal (LF)	0.73 [0.59, 0.83]	0.99 [0.94, 1.00]
Li 2021 − Internal (FL)	0.67 [0.54, 0.78]	0.99 [0.94, 1.00]
Curti 2021 − CASPR Biotech	1.00 [0.96, 1.00]	0.99 [0.94, 1.00]
Nimsamer 2021 − Internal	0.92 [0.81, 0.97]	0.99 [0.93, 1.00]
Nimsamer 2021 − Internal	0.94 [0.84, 0.98]	0.90 [0.80, 0.95]
Nimsamer 2021 − Internal	0.97 [0.87, 0.99]	0.84 [0.73, 0.91]
Nimsamer 2021 − Internal	0.94 [0.84, 0.98]	0.99 [0.93, 1.00]
Mayuramart 2021 − Internal	0.95 [0.86, 0.99]	1.00 [0.96, 1.00]



Study	Sensitivity (95%CI)	Specificity (95%CI)
Sapkal 2020 − Internal	0.92 [0.86, 0.96]	0.98 [0.96, 0.99]
Tré−Hardy 2020 − Novatec Inmunodiagnostic	0.94 [0.91, 0.97]	0.96 [0.89, 0.98]
Serrano 2020 − EuroImmun	0.81 [0.71, 0.88]	0.81 [0.74, 0.87]
Krüttgen 2020 − EuroImmun	0.85 [0.73, 0.93]	0.94 [0.78, 0.99]
Krüttgen 2020 − Epitope Diagnostics	0.99 [0.91, 1.00]	0.87 [0.69, 0.95]
Krüttgen 2020 − Mikrogen	0.85 [0.73, 0.93]	0.98 [0.84, 1.00]
Montesinos 2020 − EuroImmun	0.62 [0.53, 0.70]	0.98 [0.92, 1.00]
Krüttgen 2020 − Idvet	0.98 [0.82, 1.00]	0.92 [0.81, 0.97]
Coste 2020 − Epitope Diagnostics	0.82 [0.76, 0.87]	0.98 [0.96, 0.99]
Mutantu 2021 − Internal	0.91 [0.84, 0.95]	0.90 [0.79, 0.95]
Barchuk 2021 − Vector-Best	0.88 [0.76, 0.95]	0.99 [0.90, 1.00]
Sil 2021 − Internal	0.94 [0.87, 0.98]	0.97 [0.91, 0.99]
Tozetto−Mendoza 2021 − Internal	0.90 [0.84, 0.94]	0.97 [0.92, 0.99]
Zhou 2021 − Internal	0.99 [0.96, 1.00]	1.00 [0.97, 1.00]
Cramer 2021 − Epitope Diagnostics	0.82 [0.73, 0.89]	0.97 [0.88, 0.99]
Cramer 2021 − EuroImmun (A)	0.90 [0.82, 0.94]	0.99 [0.91, 1.00]
Cramer 2021 − EuroImmun (B)	0.88 [0.80, 0.94]	0.99 [0.91, 1.00]
Cramer 2021 − Dia.Pro	0.92 [0.84, 0.96]	0.83 [0.71, 0.91]
Cramer 2021 − Novatec Inmunodiagnostic	0.75 [0.65, 0.83]	0.99 [0.91, 1.00]
MacMullan 2021 − EuroImmun	0.84 [0.74, 0.90]	0.99 [0.93, 1.00]
zhou 2021 − Internal	0.88 [0.84, 0.91]	0.98 [0.96, 0.99]
Xiang 2021 − Livzon	0.76 [0.57, 0.88]	0.94 [0.83, 0.98]
Rychert 2021 − EuroImmun	0.88 [0.83, 0.92]	0.94 [0.87, 0.97]



Study	Sensitivity (95%CI)	Specificity (95%CI)
Tré−Hardy 2020 − Novatec Inmunodiagnostic	0.49 [0.42, 0.55]	0.98 [0.92, 1.00]
Velay 2020 − Epitope Diagnostics	0.73 [0.67, 0.79]	1.00 [0.95, 1.00]
Zhou 2021 − Internal	1.00 [0.97, 1.00]	0.96 [0.91, 0.98]
Indenbaum 2021 − Internal	0.47 [0.41, 0.52]	1.00 [0.99, 1.00]
Xiang 2021 − Livzon	0.76 [0.57, 0.88]	0.89 [0.76, 0.96]



medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Study	Sensitivity (95%CI)	Specificity (95%CI)
Velay 2020 – EuroImmun	0.84 [0.78, 0.88]	0.93 [0.86, 0.96]
Tré-Hardy 2020 – Novatec Inmunodiagnostic	0.90 [0.85, 0.93]	0.98 [0.92, 1.00]
Serrano 2020 – EuroImmun	0.92 [0.85, 0.96]	1.00 [0.96, 1.00]
Montesinos 2020 – EuroImmun	0.83 [0.76, 0.89]	0.86 [0.76, 0.92]
Indenbaum 2021 – Internal	0.80 [0.75, 0.84]	0.98 [0.96, 0.99]



Study	Sensitivity (95%CI)	Specificity (95%CI)
Thompson 2020 – Internal	0.92 [0.71, 0.98]	1.00 [0.95, 1.00]
Irsara 2021 – Siemens Healthcare	0.90 [0.85, 0.94]	0.99 [0.96, 1.00]
Putcharoen 2021 – Internal	0.98 [0.94, 1.00]	1.00 [0.98, 1.00]
Perera 2021 – GenScript Biotech	0.99 [0.96, 1.00]	0.99 [0.96, 1.00]
Nandakumar 2021 – GenScript Biotech	0.96 [0.90, 0.98]	1.00 [0.98, 1.00]



Study	Sensitivity (95%CI)	Specificity (95%CI)
Zhu 2020 – Internal	0.99 [0.87, 1.00]	0.99 [0.95, 1.00]
Büyüksünetçi 2021 – Internal	0.96 [0.86, 0.99]	0.89 [0.76, 0.96]
Mavrikou 2021 – Internal	0.90 [0.72, 0.97]	0.95 [0.68, 1.00]
Liv 2021 – Internal	0.93 [0.86, 0.97]	0.92 [0.77, 0.97]
Apostolou 2021– Embio Diagnostics	0.92 [0.86, 0.96]	0.97 [0.93, 0.99]
Zhu 2021 – Internal	0.99 [0.89, 1.00]	0.99 [0.94, 1.00]
Chaibun 2021 – Internal	0.99 [0.90, 1.00]	0.99 [0.93, 1.00]



medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Study	Sensitivity (95%CI)	Specificity (95%CI)
Montesinos 2020 – Snibe	0.53 [0.45, 0.62]	0.99 [0.94, 1.00]
Soleimani 2020 – Snibe	0.62 [0.55, 0.69]	1.00 [0.95, 1.00]
Lin 2020 – Internal	0.82 [0.65, 0.92]	0.97 [0.88, 0.99]
Krüttgen 2020 – DiaSorin	0.93 [0.76, 0.98]	0.90 [0.79, 0.95]
Coste 2020 – Snibe	0.73 [0.66, 0.79]	0.99 [0.97, 1.00]
Coste 2020 – DiaSorin	0.65 [0.58, 0.72]	1.00 [0.99, 1.00]
Rychert 2021 – DiaSorin	0.88 [0.73, 0.95]	0.99 [0.94, 1.00]
Jung 2021 – DiaSorin	0.93 [0.89, 0.96]	1.00 [0.97, 1.00]
Sekirov 2021 – DiaSorin	0.78 [0.64, 0.88]	0.95 [0.86, 0.98]
Sekirov 2021 – Abbott	0.97 [0.86, 0.99]	0.98 [0.91, 0.99]
Sekirov 2021 – Siemens Healthcare	0.94 [0.83, 0.98]	0.99 [0.93, 1.00]
Zonneveld 2021 – DiaSorin	0.70 [0.62, 0.78]	0.96 [0.92, 0.98]



Study	Sensitivity (95%CI)	Specificity (95%CI)
Montesinos 2020 – Snibe	0.59 [0.50, 0.67]	0.99 [0.94, 1.00]
Soleimani 2020 – Snibe	0.60 [0.53, 0.67]	1.00 [0.95, 1.00]
Lin 2020 – Internal	0.62 [0.44, 0.77]	0.91 [0.81, 0.96]
Coste 2020 – Snibe	0.71 [0.64, 0.77]	0.98 [0.96, 0.99]
Sekirov 2021– Ortho Clinical Diagnostics	0.90 [0.77, 0.96]	0.99 [0.93, 1.00]



medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Study	Sensitivity (95%CI)	Specificity (95%CI)
Montesinos 2020 − Snibe	0.64 [0.56, 0.72]	0.99 [0.94, 1.00]
Soleimani 2020 − Snibe	0.70 [0.63, 0.77]	1.00 [0.95, 1.00]
Sekirov 2021 − Ortho Clinical Diagnostics	0.99 [0.90, 1.00]	0.98 [0.91, 0.99]
Sekirov 2021− Roche	0.92 [0.80, 0.97]	0.99 [0.93, 1.00]
Pérez−García 2021 − Siemens Healthcare	0.87 [0.75, 0.94]	0.99 [0.93, 1.00]
Pérez−García 2021 − Roche	0.91 [0.80, 0.96]	0.99 [0.93, 1.00]
Cramer 2021 − Roche	0.90 [0.81, 0.95]	0.98 [0.84, 1.00]



Study	Sensitivity (95%CI)	Specificity (95%CI)
Serrano 2020 − Hangzhou Alltest Biotech	0.70 [0.60, 0.79]	0.98 [0.94, 0.99]
Serrano 2020 − Wuhan UNscience Biotechnology	0.86 [0.77, 0.92]	0.96 [0.91, 0.98]
Montesinos 2020 − Bio Marketing Diagnostics	0.67 [0.59, 0.75]	0.99 [0.94, 1.00]
Montesinos 2020 − Avioq	0.69 [0.60, 0.76]	0.95 [0.88, 0.98]
Montesinos 2020 − ZenTech	0.50 [0.41, 0.59]	0.99 [0.94, 1.00]
Chen 2020 − Internal	0.94 [0.60, 0.99]	0.88 [0.62, 0.97]
Coste 2020 − Dynamiker Biotechnology	0.75 [0.68, 0.81]	0.98 [0.96, 0.99]
Mulchandani 2020 − UK−RTC	0.92 [0.89, 0.95]	0.98 [0.97, 0.98]
McAulay 2020 − BTNX Inc	0.95 [0.92, 0.97]	0.98 [0.93, 0.99]
McAulay 2020 − BTNX Inc	0.91 [0.87, 0.93]	1.00 [0.96, 1.00]
McAulay 2020 − Acon Laboratories	0.94 [0.88, 0.97]	0.98 [0.93, 0.99]
McAulay 2020 − SD Biosensor	0.91 [0.80, 0.96]	1.00 [0.96, 1.00]
Daoud 2020 − Raybiotech	0.69 [0.57, 0.78]	1.00 [0.96, 1.00]
Daoud 2020 − Healgen	0.74 [0.63, 0.82]	1.00 [0.96, 1.00]
Conte 2021 − Bioclin	0.85 [0.76, 0.91]	0.97 [0.77, 1.00]
Conte 2021 − Livzon	0.36 [0.27, 0.46]	0.97 [0.77, 1.00]
Kaku 2021 − Kurabo	0.48 [0.40, 0.56]	0.99 [0.96, 1.00]
Robertson 2021 − UK−RTC	0.97 [0.95, 0.99]	0.99 [0.98, 1.00]
Jones 2021 − UK−RTC	0.92 [0.89, 0.95]	0.98 [0.97, 0.98]
Jones 2021 − Orient Gene	0.94 [0.90, 0.96]	0.97 [0.96, 0.98]
Jones 2021 − SureScreen Diagnostics	0.89 [0.84, 0.92]	0.99 [0.98, 0.99]
Jones 2021 − Biomerica	0.94 [0.91, 0.96]	0.97 [0.96, 0.98]



medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Study	Sensitivity (95%CI)	Specificity (95%CI)
Serrano 2020 – Hangzhou Alltest Biotech	0.32 [0.23, 0.43]	0.94 [0.88, 0.97]
Serrano 2020 – Wuhan UNscience Biotechnology	0.76 [0.66, 0.84]	0.90 [0.83, 0.94]
Montesinos 2020 – Bio Marketing Diagnostics	0.48 [0.40, 0.57]	0.99 [0.94, 1.00]
Montesinos 2020 – Avioq	0.69 [0.60, 0.76]	0.95 [0.88, 0.98]
Montesinos 2020 – ZenTech	0.69 [0.60, 0.76]	0.99 [0.94, 1.00]
Coste 2020 – Dynamiker Biotechnology	0.79 [0.72, 0.84]	0.96 [0.93, 0.97]
Daoud 2020 – Raybiotech	0.59 [0.47, 0.69]	0.99 [0.95, 1.00]
Daoud 2020 – Healgen	0.66 [0.55, 0.76]	1.00 [0.96, 1.00]
Daoud 2020 – Internal	0.87 [0.78, 0.93]	0.99 [0.95, 1.00]
Conte 2021 – Bioclin	0.55 [0.44, 0.65]	0.97 [0.77, 1.00]
Conte 2021 – Livzon	0.30 [0.21, 0.40]	0.97 [0.77, 1.00]
Kaku 2021 – Kurabo	0.23 [0.17, 0.31]	1.00 [0.97, 1.00]



Study	Sensitivity (95%CI)	Specificity (95%CI)
Velay 2020 – Biosynex	0.84 [0.78, 0.88]	0.89 [0.81, 0.93]
Velay 2020 – Servibio	0.65 [0.58, 0.71]	1.00 [0.95, 1.00]
Serrano 2020 – Wondfo	0.90 [0.82, 0.95]	0.87 [0.81, 0.92]
Montesinos 2020 – Bio Marketing Diagnostics	0.72 [0.63, 0.79]	0.99 [0.94, 1.00]
Montesinos 2020 – Avioq	0.69 [0.60, 0.76]	0.95 [0.88, 0.98]
Montesinos 2020 – ZenTech	0.71 [0.63, 0.78]	0.99 [0.94, 1.00]
Wu 2020 – ALLTEST	0.91 [0.69, 0.98]	0.99 [0.92, 1.00]
Wu 2020 – Dynamiker Biotechnology	0.85 [0.62, 0.95]	0.99 [0.92, 1.00]
Wu 2020 – TONYAR Biotech	0.85 [0.62, 0.95]	0.99 [0.92, 1.00]
Wu 2020 – Wondfo	0.91 [0.69, 0.98]	0.99 [0.92, 1.00]
Cramer 2021 – CTK Biotech	0.79 [0.69, 0.87]	0.98 [0.81, 1.00]
Conte 2021 – Bioclin	0.85 [0.76, 0.91]	0.97 [0.77, 1.00]
Conte 2021 – Livzon	0.44 [0.34, 0.55]	0.97 [0.77, 1.00]
Conte 2021 – Wondfo	0.48 [0.37, 0.58]	0.97 [0.77, 1.00]
Wang 2021 – Internal	0.97 [0.92, 0.99]	0.95 [0.91, 0.97]
Pérez-García 2021 – ALLTEST	0.61 [0.50, 0.71]	0.99 [0.93, 1.00]
Pérez-García 2021 – Innovita	0.73 [0.63, 0.82]	0.99 [0.93, 1.00]
Pérez-García 2021 – Epigentek	0.67 [0.56, 0.77]	0.96 [0.88, 0.99]
Jones 2021 – Orient Gene	0.94 [0.90, 0.96]	0.96 [0.95, 0.97]
Jones 2021 – SureScreen Diagnostics	0.94 [0.90, 0.96]	0.97 [0.96, 0.98]
Jones 2021 – Biomerica	0.95 [0.92, 0.97]	0.92 [0.91, 0.93]



medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Study	Sensitivity (95%CI)	Specificity (95%CI)
Cerutti 2020 − SD Biosensor	0.70 [0.61, 0.78]	1.00 [0.98, 1.00]
Albert 2020 − Abbott	0.78 [0.64, 0.88]	1.00 [0.99, 1.00]
Pérez−García 2021 − Abbott	0.60 [0.52, 0.67]	1.00 [0.97, 1.00]
Eleftheriou 2021 − Abbott	0.82 [0.69, 0.90]	1.00 [0.99, 1.00]
Igloi 2021 − SD Biosensor	0.85 [0.79, 0.89]	0.99 [0.99, 1.00]
Kurihara 2021− Mizuho Medy Co	0.74 [0.64, 0.83]	1.00 [0.99, 1.00]
Kim 2021 − Internal	0.89 [0.73, 0.96]	0.98 [0.92, 0.99]
Abusrewil 2021 − Fujirbio	0.77 [0.48, 0.93]	0.94 [0.60, 0.99]
Abusrewil 2021 − RapiGEN	0.62 [0.39, 0.81]	0.98 [0.83, 1.00]
Abusrewil 2021 − Abbott	0.75 [0.49, 0.90]	0.95 [0.68, 1.00]
Abusrewil 2021 − Acon Laboratories	0.97 [0.76, 1.00]	0.95 [0.68, 1.00]
Abusrewil 2021 − Assut Europe	0.69 [0.36, 0.90]	0.98 [0.83, 1.00]
Abusrewil 2021 − Orient Gene	0.50 [0.25, 0.75]	0.96 [0.72, 1.00]
Abusrewil 2021 − Certest Biotec	0.61 [0.31, 0.85]	0.95 [0.66, 0.99]
Abusrewil 2021 − BioPerfectus	0.77 [0.48, 0.93]	0.96 [0.70, 1.00]
Abusrewil 2021 − AMP Diagnostics	0.81 [0.47, 0.96]	0.94 [0.63, 0.99]
Torres 2021 − Abbott	0.48 [0.38, 0.59]	1.00 [0.99, 1.00]
Gupta 2021 − SD Biosensor	0.81 [0.71, 0.88]	0.99 [0.97, 1.00]
Oh 2021 − SD Biosensor	0.18 [0.09, 0.33]	0.99 [0.94, 1.00]
Ferté 2021 − Abbott	0.63 [0.46, 0.77]	1.00 [0.99, 1.00]
Kyritsi 2021 − ProGnosis Biotech	0.85 [0.79, 0.90]	1.00 [0.99, 1.00]
Jakobsen 2021 − SD Biosensor	0.70 [0.63, 0.75]	0.99 [0.99, 1.00]



Study	Sensitivity (95%CI)	Specificity (95%CI)
Charpentier 2020 − Abbott	0.96 [0.87, 0.99]	0.95 [0.86, 0.99]
Zonneveld 2021 − Abbott	0.75 [0.67, 0.82]	1.00 [0.97, 1.00]
Barchuk 2021− Abbott	0.63 [0.48, 0.75]	0.99 [0.90, 1.00]
Rychert 2021 − Abbott	0.90 [0.76, 0.96]	0.99 [0.94, 1.00]
Jung 2021 − Abbott	0.96 [0.92, 0.98]	0.99 [0.96, 1.00]



Study	Sensitivity (95%CI)	Specificity (95%CI)
Orsi 2021 − SD Biosensor	0.86 [0.75, 0.93]	0.99 [0.91, 1.00]
Orsi 2021 − NanoEntek	0.93 [0.83, 0.97]	0.99 [0.91, 1.00]
Pérez−García 2021 − SD Biosensor	0.66 [0.59, 0.73]	0.97 [0.94, 0.99]
Baccani 2021 − SD Biosensor	0.38 [0.22, 0.57]	1.00 [0.95, 1.00]
Baccani 2021 − Menarini	0.38 [0.23, 0.56]	1.00 [0.95, 1.00]



medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .



medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .







medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .







medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .







medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .







medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .







medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint **(which was not certified by peer review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .





Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	3
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	3
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	4
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	4
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	4

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Section and Topic	Item #	Checklist item	Location where item is reported
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	4
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	4
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	4
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	4
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	4
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	4
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	4
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	4
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	4
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	4
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	4
	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	4
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	NA
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	4
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	5 (Fig. 1)
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	5
Study characteristics	17	Cite each included study and present its characteristics.	5
Risk of bias in	18	Present assessments of risk of bias for each included study.	NA

medRxiv preprint doi: https://doi.org/10.1101/2022.11.29.22282895; this version posted November 29, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

It is made available under a CC-BY-NC-ND 4.0 International license .

Section and Topic	Item #	Checklist item	Location where item is reported
studies			
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	5
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	5
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	5 (Fig. 4-10)
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	5
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	5
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	5
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	5
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	6
	23b	Discuss any limitations of the evidence included in the review.	6
	23c	Discuss any limitations of the review processes used.	6
	23d	Discuss implications of the results for practice, policy, and future research.	6
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	4
	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	4
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	4
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	7
Competing interests	26	Declare any competing interests of review authors.	8
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	9

NA: not applicable; PRISMA: Preferred Reporting Items for Systematic Reviews and Meta-Analyses.